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ABSTRAT 
 
The Choroid Plexus as a sensor of peripheral inflammation 
Particular interest has been raised in the last few years, regarding the contribution of the immune 
system in neurological and psychiatric diseases. It is recognized that an inflammatory component 
underlies disorders such as Alzheimer’s disease and multiple sclerosis. However, whether these 
are a consequence, a cause, or just a trigger of disease progression remains to be clarified. In 
this context, understanding how peripheral inflammatory stimulus reach the brain may contribute 
to better understand the mechanisms involved in such conditions. Most studies on the 
communication between the periphery and the central nervous system (CNS) focus on the blood-
brain barrier, which is composed by the endothelial cells of the brain capillaries. However, the 
blood-cerebrospinal fluid barrier (BCSFB) may as well convey signals from the periphery into the 
CSF and backwards. The BCSFB is formed by the choroid plexus (CP) epithelial cells. Given its 
role as the major producer of the CSF, and the presence of several receptors and transporters 
both in the apical and in the basolateral membranes, the CP is ideally positioned to transmit 
signals between the immune and the CNS. 
In the present study we address the CP response to inflammatory stimuli induced in the 
periphery. We show that the CP displays a specific, rapid and transient response to an acute 
inflammatory stimulus induced by the intraperitoneal administration of the Gram negative 
bacteria cell wall lipopolysaccharide (LPS). As soon as 1h after the injection, the CP responds by 
altering the expression of several genes. This response reaches a maximum at 3h, in which the 
level of 324 (out of 24 000 studied) transcripts are altered, and returns to the basal profile for 
most of the transcripts at 72h. Most of the up-regulated genes belong to immune-mediated 
cascades while those down-regulated encode for proteins involved in the maintenance of the CP 
barrier function.  
When LPS is administered repetitively every 2 weeks for 3 months, the CP response persists for 
longer periods but is attenuated. The biological pathway with higher up-regulation includes genes 
encoding for proteins that facilitate cells entry into the CSF, which may be particularly relevant in 
diseases such as multiple sclerosis. 
Of notice, in both conditions of acute and sustained inflammatory response, we observed altered 
expression of genes that participate in the innate immune response to infection by 
microorganisms, and that are related to iron homeostasis. In both conditions, the CP responds 
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by decreasing iron availability for bacterial growth. Specifically, lipocalin 2, a sequester for 
bacteria iron-loaded siderophores is rapidly secreted into the CSF, persisting in the sustained 
inflammatory conditions. In addition, the CP is here suggested to play an identical role of that 
played by the liver, in regulating iron uptake and release, through the synthesis and secretion of 
hepcidin. Of interest, iron deregulation has been implicated in neurodegenerative diseases 
including Alzheimer’s disease and multiple sclerosis. 
Taken together, the data presented here highlights the role of the CP in mediating immune 
signals into the brain. How, this ultimately corresponds to neuroprotective or deleterious 
consequences for the brain and how this may relate to diseases of the CNS needs to be further 
investigated.  
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RESUMO 
 
Os Plexus Coroideus como sensores da inflamação periférica 
Nos últimos anos tem aumentado o interesse no estudo da participação do sistema imunológico 
em doenças neurológicas e psiquiátricas. A inflamação é hoje aceite com estando presente em 
doenças como a de Alzheimer e a esclerose múltipla. No entanto, ainda está por esclarecer se 
esta é uma causa, consequência ou estímulo de progressão e agravamento da doença. Neste 
contexto, a compreensão do modo como estímulos inflamatórios periféricos influenciam o 
cérebro pode contribuir para a compreensão dos mecanismos envolvidos nestas doenças. A 
maioria dos estudos sobre a comunicação entre a periferia e o sistema nervoso central têm 
incidido na barreira hemato-encefálica, que é constituída pelas células endoteliais dos capilares 
sanguíneos. No entanto, a barreira sangue-líquido céfalo-raquidiano (BCSFB) pode, igualmente, 
participar na transmissão de sinais entre a periferia e o CSF. A BCSFB é formada pelas células 
epiteliais dos plexus coroideus (CP). Tendo como função principal a produção de CSF, e uma vez 
que possuem vários receptores e transportadores, tanto na membrana apical como na 
basolateral, os CP estão idealmente posicionados para facilitar a interacção entre os sistemas 
imunológico e nervoso central. 
O trabalho desenvolvido nesta tese avalia a resposta dos CP a estímulos inflamatórios periféricos 
induzido pela administração intraperitoneal do lipopolissacarídeo (LPS) da parede de bactérias 
de Gram negativo. Quando este estímulo é agudo, observa-se uma resposta específica, rápida e 
transitória nos níveis de expressão de vários genes. Esta resposta é evidente 1h após a injecção, 
atinge um máximo às 3h, com a expressão diferencial de 324 (num total de 24 000 estudados) 
transcritos, e volta ao estado basal para a maioria dos transcritos ao fim de 72h. De entre os 
genes cuja expressão se encontra alterada os que têm expressão mais aumentada codificam 
moléculas envolvidas em cascatas imunológicas, enquanto que aqueles com expressão mais 
diminuída incluem genes que codificam proteínas que participam na manutenção da função de 
barreira do CP. 
Quando o LPS é administrado a cada 2 semanas durante 3 meses, a resposta dos CP persiste 
mais tempo e é de pequena amplitude. A via metabólica com maior aumento na expressão inclui 
genes que codificam proteínas que facilitam a migração de células para o CSF, o que pode ser 
relevante em doenças como a esclerose múltipla.  
De realçar, tanto na resposta inflamatória aguda como na continuada, observa-se expressão 
 x 
alterada de genes que participam na resposta imunológica inata à infecção por 
microorganismos, e que estão relacionados com o metabolismo do ferro. Em ambos os casos, o 
CP responde diminuindo a disponibilidade de ferro necessário para o crescimento bacteriano. 
Especificamente, a lipocalina 2, uma proteína que sequestra sideroforos bacterianos que ligam 
ferro, é rapidamente segregada para o CSF; uma resposta que persiste na inflamação 
continuada. Para além disso os resultados obtidos sugerem que o CP desempenha uma função 
idêntica à do fígado na regulação da captação e libertação de ferro, através da regulação da 
síntese e segregação de hepcidina. É de notar que alterações no metabolismo do ferro têm sido 
implicadas em doenças neurodegenerativas como a doença de Alzheimer e a esclerose múltipla. 
No seu conjunto, os resultados desta tese apontam para uma função clara do CP na transmissão 
da resposta inflamatória periférica para o cérebro. Se a consequência final desta resposta é 
benéfica ou deletéria para o cérebro, ou se contribui para doenças do sistema nervoso central 
fica ainda por esclarecer.  
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THESIS ORGANIZATION 
 
The present dissertation is organized in 7 different chapters. Chapter 1 introduces the subject, 
chapters 2-6 represent the experimental work (in the form of articles) and chapter 7 the general 
discussion and future perspectives of the work. The manuscripts presented in chapters 2 and 3 
have been already published in the journals Neuroscience and Journal of Cerebral Blood Flow & 
Metabolism, respectively. The manuscripts presented in chapters 4, 5 and 6 will soon be 
submitted for publication. 
 
In chapter 1, a general introduction raises the major questions addressed in this thesis. A brief 
explanation of the choroid plexus (CP) as part of the barriers system of the brain is given. Its 
location, morphology, as well as its major functions and those of some of the secreted proteins 
are described. A review on the relevance of these barriers as mediating the immune response of 
the central nervous system (CNS) is discussed. A brief comparison between the blood-brain 
(BBB) and the blood-cerebrospinal fluid (CSF) barriers (BCSFB) is made. Finally, a description of 
the innate immune response in the periphery, its proposed implications in the CP and its 
recognized impact in the brain, with particular attention to the alterations of iron metabolism as 
an immune mechanism of defence, are given. 
 
In chapter 2, the work “The choroid plexus response to peripheral inflammatory stimulus”, 
shows that the expression of major CP proteins, in particular of lipocalin-type prostaglandin D2 
synthase (L-PTGDS), is increased upon peripheral administration of lipopolysaccharide (LPS). 
This is the first evidence of a CP constitutively expressed protein whose secretion is up-
regulated by peripheral inflammation. Given the role of L-PTGDS in prostaglandin metabolism it 
is suggested that this might constitute a mediator of immune signals between the periphery 
and the brain. 
 
In chapter 3, the work “Lipocalin 2 is a choroid plexus acute-phase protein”, shows that 
lipocalin2 (LCN2) is produced by the CP as a component of the innate immune response. It is 
proposed that LCN2 may protect the CNS from infection. The relevance of LCN2, at the 
BCSFB, as a bacteriostatic component in situations of bacterial infections of the brain is 
discussed. 
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In chapter 4, the work “Altered iron metabolism is part of the choroid plexus response to 
peripheral inflammation” shows that the CP alters iron metabolism during inflammation, 
probably as a mechanism to decrease iron availability for the brain. The relevance of such 
response for bacteria access to and distribution within the brain is discussed. 
 
In chapter 5, the work “The choroid plexus displays an acute-phase response to peripheral 
inflammation”, shows a rapid and transient response of the CP transcriptome to peripheral 
inflammation, as revealed by microarray analysis. How this response is established and what are 
its consequences for the brain are discussed. 
 
In chapter 6, the work “The choroid plexus response to a sustained peripheral inflammatory 
stimulus” shows that prolonged exposition to LPS leads to an adaptative response when 
compared to an acute stimulation, even though the expression of key mediators of the 
inflammatory response are maintained. 
 
The general discussion of the present dissertation, as well as the final conclusions and future 
perspectives, is presented in chapter 7. 
 
 
1  
Introduction 
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1.1. The brain as an immune-privileged organ 
1.1.1. The central nervous system barriers 
The brain is an unusual tissue since it is protected from free exchange with the blood by blood-
brain barriers. Due to these barriers, that inhibit the free diffusion of hydrophilic molecules across 
the brain capillaries, the central nervous system (CNS) was traditionally described as an immune-
privileged site. This view was additionally based on observations such as that: allografts survive 
longer in the CNS than in other organs (Fuchs and Bullard, 1988); the CNS lacks lymphatic 
vessels; the CNS is devoided of classical antigen-presenting cells, such as dendritic cells 
(Matyszak and Perry, 1996) and; the CNS lacks constitutive expression of major 
histocompatibility complex class I and II molecules on parenchymal cells (Perry, 1998). 
The CNS homeostasis is essential for the proper function of neuronal cells and is the presence of 
blood-brain barriers that protects the brain from the constant oscillation observed in the 
concentrations of blood constituents. There are two main barriers: the blood-brain barrier (BBB) 
and the blood-cerebrospinal fluid (CSF) barrier (BCSFB) (Abbott, 2005). In the context of this 
dissertation BBB and BCSFB will be extensively discussed. Particularly, the focus will rely on how 
the BCSFB provides signals into the brain in conditions of peripheral inflammation. 
1.1.2. The blood-brain barrier 
The BBB is formed by the endothelium lining the brain capillaries. This endothelium differs from 
that of most other capillaries in the rest of the body by the presence of extensive intercellular tight 
junctions, by the absence of fenestrations and by sparse pinocytic transport (Ballabh et al., 
2004). The BBB impedes the influx of most components from the blood into the brain. Small 
lipophilic molecules such as O2 and CO2 can diffuse freely across endothelial cells along their 
concentration gradient. Nutrients like glucose and amino acids enter into the brain trough specific 
transporters. In addition, endothelial cells have receptors that bind certain molecules and 
transport them by receptor-mediated endocytosis, as is the case for molecules like insulin, leptin 
and transferrin (TF) (Pardridge et al., 1985; Zhang and Pardridge, 2001). 
The circumventricular organs, that include the area postrema, median eminence, pineal gland, subfornical 
organ, and lamina terminalis, are specialized brain regions devoided of BBB. The circumventricular organs 
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are characterized by their small size, high permeability and fenestrated capillaries. The exchanges with the 
periphery in those regions is higher, the capillary endothelium is permeable, but those regions do not form 
an open door into the brain parenchyma by virtue of tight junctions between specialized ependymal cells, 
tanycytes, that surround them (Brightman and Kadota, 1992). 
1.1.3. The blood-cerebrospinal fluid barrier  
Although most studies performed in the barrier systems of the brain address the BBB, other 
important barrier is the BCSFB constituted by the choroid plexus (CP) epithelial cells. Of notice, 
the blood vasculature that irrigates the CP is also fenestrated, thus not restricting the cellular 
movement of molecules. Their diffusion into the CSF is prevented by the tight junctions that 
characterize the CP epithelial monolayer. The CP epithelial cells, responsible for producing most 
of the CSF, separate, therefore, the blood from the CSF. Similarly to the BBB, the BCSFB 
restricts passage of blood-born molecules, but displays transporters (for instance for glucose and 
amino acids) and receptors, that condition the composition of the CSF (Chodobski and 
Szmydynger-Chodobska, 2001). In addition, the CP in itself contributes to the composition of the 
CSF by secreting several carrier proteins and growth factors. 
1.1.4. Two barriers: two major cell types (endothelial versus epithelial cells) 
The characteristic hallmark of the BBB and BCSFB is the presence of intercellular junctions 
between endothelial cells (Pachter et al., 2003; Persidsky et al., 2006) of the brain capillaries and 
between epithelial cells of the CP (Szmydynger-Chodobska et al., 2007) that physically restrict the 
passage of substances between cells. Nevertheless the morphological distribution of the proteins 
that constitute the referred intercellular junctions differs between these two barrier systems. 
The intercellular junctions of the BBB endothelial cells and of the CP epithelial cells are 
composed by tight junctions and the adherens junctions (Kniesel and Wolburg, 2000; Vorbrodt 
and Dobrogowska, 2003). The tight junctions are constituted by three transmembranar proteins: 
claudins, occludins, and junctional adhesion molecule. The adherens junctions are composed by 
the cadherins. The associated cytoplamatic accessory proteins namely zonula occludens 
proteins, in the case of the tight junctions, and catenins, for the adherens junctions, connect the 
transmembranar proteins with the cell cytoskeleton (Vorbrodt and Dobrogowska, 2003; Kniesel 
and Wolburg, 2000) (Figure 1.). This binding is responsible for the maintenance of the structural 
integrity of the epithelium and the endothelium. 
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Figure 1. Schematic representation of the distribution of intercellular junctions. The localization of the proteins responsible for the intercellular 
junctions is different between endothelial cells of the BBB and epithelial cells of the CP. JAM - junctional adhesion molecule; ZO-1, -2, -3 - zonula 
occludens protein 1, 2, 3. 
 
When considering the morphological distribution of the intercellular junctions, the tight junctions in the 
CP epithelial cells are more concentrated in a short length of the apical side, close to the CSF, while 
the tight junctions of the BBB are localized along the entire length of the contacting membrane of the 
endothelial cells (Vorbrodt and Dobrogowska, 2003). As an example, immunostainning for occludin 
appears solely in the area of tight junctions formed between the apical segments of adjacent epithelial 
cells, but their concentration in the BBB is high along the contacting membrane of the cell both in 
humans and in mice (Vorbrodt and Dobrogowska, 2003). However there is much less information 
available on the presence and localization, at the ultrastructural level, of various intercellular junctions 
proteins in the CP epithelium than in the BBB endothelium. 
When the transfer of blood-born molecules or cells into the brain is considered, leakage of the barrier 
function is necessary. Therefore, the proteins that constitute the barriers of the brain are expected to 
be influenced by conditions such as inflammation, which will be further discussed in chapter 5. 
Although the endothelial cells (of the BBB) and the epithelial cells (of the BCSFB) differ on the 
morphological distribution of the intercellular junctions they share some common features. For 
instance, a fundamental function of both the epithelium and endothelium is to separate different 
compartments within the organism and to regulate the exchange of substances between them. In 
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fact, the endothelium is one type of epithelium; it is a highly specialized active interface between blood 
and the underlying tissues, maintaining vascular tone, thrombo-resistance and selective permeability 
to cells and proteins (Methe et al., 2007). Particular to epithelial cells is the presence of polarity and 
the higher complexity in terms of cytoplasmatic organelles in comparison with endothelial cells. 
The epithelial cells have basal lamina and have a higher secretory capacity than endothelial cells, 
as revealed by the higher number of mitochondria in their cytoplasm. Epithelial cells play an 
important role in physiological and pathophysiological situations, with organ-, tissue-, type-, and 
function-specific patterns. The complete set of functions of the CP epithelium is far from clearly 
understood. However, given its location, it is expected that it can fulfil some of the features 
attributed to other types of epithelial cells: physical protection (e.g. epiderme, internal recovery 
superficies of the organs); absorption (small intestine), secretion (caliciformes cells), secretion 
and transport (renal tubs, vesicular biliar), and immune response (respiratory epithelium) 
(Chignard et al., 2001; Nemes and Steinert, 1999; Thompson et al., 1995). 
1.2. Choroid plexus 
1.2.1. Choroid plexus morphology 
The CP is a highly phylogenetically and ontogenetically conserved structure. The CP develops early 
during embryogenesis and already constitutes a functional barrier within the first weeks of gestation 
(Dziegielewska et al., 2001). During embryogenesis its permeability is higher allowing low 
molecular weight compounds to enter the brain more easily than in adulthood. During embryonic 
development, the CP occupies a proportional larger volume of the total brain and it is essential for 
the proper CNS formation due to the secretion, into the CSF, of morphogens, mitogens and specific 
growth factors (Bondy et al., 1990; Yamamoto et al., 1996; Figueiredo et al., 1993; Strazielle and 
Ghersi-Egea, 2000). The CP is positioned within the ventricles of the brain: one in each lateral, one 
in the third and one in the fourth ventricles. Grossly, the CP is lobulated with a unique and 
continuous line of epithelial cells originating from the ependymal line of the ventricles and floats into 
the CSF space inside the ventricles. The CP is essentially constituted by a continuous strand of 
cuboidal epithelial cells, which rests upon a basal lamina and contains a central core formed by 
connective and highly vascularised tissue. The apical side of the epithelial cells faces the CSF and 
contains numerous villosities while the basal side faces the blood, lying in the stroma side in 
contact with a huge number of capillaries. In the central core of the connective tissue it is possible 
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to find, in addition to the fenestrated capillaries, dendritic cells, fibroblasts and macrophages. The 
basolateral side of the CP epithelial cells is, therefore, in contact with molecules and cells that freely 
pass through the brain capillaries, and also with the proteins and other molecules secreted by 
these other various cell types. Ultrastructurally, the epithelial cell contains numerous mitochondria, 
Golgi apparatus and a smooth endoplasmic reticulum which demonstrates that it is a structure with 
great synthetic capacity. Additionally, high number of vesicles with lisossomal characteristics is 
observed in the cytoplasm. In the apical side, lying over the microvillus layer, there are cells 
attached, designated as epiplexus cells or Kolmer cells (Pietzsch-Rohrschneider, 1980). In addition 
to these cells, free floating and supraependymal cells are observed in the lumen of the ventricles 
(Ling et al., 1998; Matyszak et al., 1992; Nataf et al., 2006; McMenamin et al., 2003). These cells, 
altogether referred as intraventricular macrophages, could represent, the first line of defence able to 
react against brain infections, after they transverse the CP. 
 
 
Figure 2. Morphological representation of the choroid plexus. The choroid plexus is formed by epithelial cells originated from the ependymal cell 
layer of the ventricules. Those epithelilal cells rest upon a basal lamina and inner core of highly vascularized connective tissue. The apical side of the 
epithelial cells faces the cerebrospinal fluid and contains villosities. Adjacent epithelial are bound together by tight junctions. Macrophages, dendritic 
cells, fibroblasts and fenestrated capillaries are present throughout the stroma. In the apical side, attached to the villosities are the epiplexus cells. 
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The intraventricular macrophages deserve some additional considerations given their role as 
scavenger cells and the participation in immunological responses within the ventricular system. 
Features of intraventricular macrophages are consistent with other mononuclear phagocytes, 
given their positive immunoreactivity for the presence of complement receptor 3, major 
histocompatibility complex class I and II antigens, leucocyte common antigen, and macrophage 
antigen (Ling et al., 1998). The expression of these antigens is noticeably enhanced following the 
intraperitoneally injection of lipopolysaccharide (LPS) in rats (Lu et al., 1994). Remarkably, the 
intraventricular macrophages are induced to increase the expression of major histocompatibility 
complex class II antigen after LPS or interferon-gamma injections. This suggests that these cells 
can function as antigen presenting cells in the brain ventricles (as macrophages do in the 
periphery) in situations of infection and injury. Several mechanisms might then contribute, within 
the brain, to respond to peripheral stimulus. Among these, the expression of transferrin receptor 
(TFR), as detected with OX-26 immunohistochemistry, is also upregulated after these treatments 
(Lu et al., 1995). These will conduct to a decrease of iron in the environment for the pathogens 
and, at the same time, the iron that is being endocytosed can be used in oxidative killing or 
immunological activation. Other characteristic in which intraventricular macrophages resemble 
peripheral macrophages is the fact that they are also elicited to display a de novo expression of 
nitric oxide synthase-like immunoreactivity following intracerebral injection of LPS (Ling et al., 
1998). Whether this also occurs upon stimulus induced in the periphery is unknown but it could 
represent an additional mechanism of defence that can help in the protection of the brain against 
bacterial infections. 
The number of intraventricular macrophages increases considerable with age in the rat (Ling et 
al., 1998). This increase seems to result partly from the proliferation of local cells but can also 
represent increased recruitment of blood monocytes that reach the ventricle through the CP 
epithelium. Whether this increase relates to decreased barrier function with age and how does it 
correlate with development of brain neurodegenerative disease remains to be studied. 
1.2.2. Choroid plexus functions 
1.2.2.1. Production of cerebrospinal fluid 
The brain has two fluid environments: the brain interstitial fluid, which surrounds the 
neurons and glia, and the CSF, which fills the ventricles and the subarachnoid space. The 
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best recognized function of the CP is the production of CSF (Speake et al., 2001). 
Maintenance of the equilibrium in volume and composition of the CSF is vital for a normal 
brain function, ensuring an optimal environment for the neuronal cells. The CSF is a clear, 
slightly viscous liquid with few cells and a protein concentration about 10 times lowers then 
the one of the blood (Segal, 2001). Most of the CSF is generated by the CP with the 
remainder 10-30% being of extrachoroidal origin (reviwed by Chodobski and Szmydynger-
Chodobska, 2001). The large secretory activity of the CP is in part provided by the high 
number of mitochondria. Another important feature of the CP is the high water permeability, 
made possible by the abundant expression of the water channel, Aquaporin-1, on the apical 
side of the membrane. 
Since the CSF surrounds the CNS and exchanges with the brain interstitial fluid it clearly 
participates in the delivery of nutrients into the brain and also in the removal of waste products 
produced by the brain. For that, the CP is well equipped with transporters and receptors, both in 
the apical and basolateral membranes. Examples are the transport of vitamin C and the disposal 
of iodine. Such CP functions are responsible for the constant refreshment of CSF, essential for 
normal brain metabolism. In humans the CSF volume is 80-150mL and is estimated that 600mL 
of CSF are produced every 24h, which is enough to replace existing CSF three to four times per 
day (Wright, 1978). 
 
1.2.2.2. Major proteins produced by the choroid plexus 
The CP is ideally located to distribute molecules both locally and globally to the brain due to its 
secretory ability into the CSF. The CP possesses numerous specific transport systems, 
contains an array of receptors (Table 1) and also serves as a source of biologically active 
products. The CP epithelium is not only a target but also a source of neuropeptides, growth 
factores and cytokines for the CSF. Of notice, the proteins and molecules produced by the CP 
are well recognized as morphogens, mitogens and trophic factors important for the 
development of the CNS, namely by influencing axonal guidance and cell migration. In table 3 
are listed some of the proteins already described to be secreted by the CP. Of notice, 
interleukin-1 beta (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor (TNF) have been 
described to be secreted by the CP in response to inflammation (Quan et al., 1998; Quan et 
al., 1999; Vallieres and Rivest, 1997). 
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Table modified from Chodobski, A. and Szmydynger-Chodobska, J., 2001. 
 
One of the initial aims of the present study was to investigate how the levels of major proteins 
constitutively expressed by the CP are influenced by peripheral inflammation (chapter 2). 
Additionally, the CP secretome, by influencing the CSF composition, might be involved in 
protecting against or mediating deleterious signals originated in the periphery to the brain. This 
will be further discussed in chapter 5. 
We will next briefly describe the function of major proteins constitutively expressed by the CP. 
A. Transthyretin 
Transthyretin (TTR), formerly designated as prealbumin due to its migration properties in native 
electrophoresis in relation to albumin (Ingbar, 1958), is a 55-kDa tetrameric protein synthesized 
mainly by the liver and by the CP (Dickson et al., 1985; Herbert et al., 1986) from where it is 
secreted into the blood and the CSF, respectively . TTR synthesis represents 20% of the total 
protein synthesized by the CP. The TTR expression is well conserved throughout evolution, starting 
in fish; and is an early event during mammalian embryogenesis, first in the thela choroidea 
(Murakami et al., 1987; Thomas et al., 1988) that will originate the CP, and later in the liver. 
TTR is a plasma and CSF carrier for thyroxine (T4) and retinol (when bound to the retinol-binding 
protein) (Palha, 2002). Although TTR has been initially proposed to be essential to mediate 
thyroid hormone transfer into the tissues, particularly into the brain across the BCSFB, studies 
with a TTR-null mice strain have shown that TTR is not necessary for thyroid hormones entry into 
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and distribution within the brain and other tissues, or for the maintenance of an euthyroid status 
(Palha et al., 1994; 1997; 2000; Palha, 2002). Recently, TTR has been associated with other 
functions: TTR is able to bind Alzheimer Amyloid beta-peptide in vitro (Schwarzman et al., 1994) 
and, by sequestering it in CSF has been suggested to prevent amyloid formation (Golabek et al., 
1995; Buxbaum et al., 2008). In accordance, decreased TTR levels in the CSF have been 
described in patients with Alzheimer disease (AD) (Serot et al., 1997). In agreement, experiments 
using TTR-null mice have shown that in the absence of TTR mice display spatial reference 
memory impairment compared to age-matched wild-type animals (Sousa et al., 2007). Of 
interest, in the absence of TTR, mice display decreased depression and anxiety-like behaviours, 
probably by modulation of the noradrenergic system (Sousa et al., 2004). One possible 
explanation for this phenotype could be hypothyroxinemia and hypovitaminosis A during 
embryonic development, since both thyroid hormone and retinol are requested for normal CNS 
formation and development. Of interest, certain mutations in the TTR gene have amyloidogenic 
potential that result in TTR protein deposition in peripheral nerves and cardiomyocytes in humans 
(Saraiva, 2002). 
TTR has been implicated in various other functions. Among these, a single report implicates TTR as 
an endogenous anti-inflammatory mediator given its ability to inhibit, in vitro, monocyte and 
endothelial IL-1β production (Borish et al., 1992). While, in the liver, TTR is a negative acute-phase 
protein (Birch and Schreiber, 1986), subcutaneous injection of turpentine did not influence CP Ttr 
expression (Dickson et al., 1986). The differential response in the liver when compared to the CP 
possibly results from tissue specific transcription modulators (Yan et al., 1990; Costa et al., 1990). 
It seems, therefore, that the precise functions of TTR, particulary within the brain, are far from 
being clearly understood.  
B. Lipocalin-type prostaglandin D2 synthase 
Lipocalin-type prostaglandin D2 synthase, also known as β-tracer, is a 30 kDa glycoprotein that 
catalyzes the formation of prostaglandin D2 (PGD2) from prostaglandin H2 (PGH2), the major 
prostanoid brain (Urade and Hayaishi, 2000). L-PTGDS is involved in the regulation of various 
physiological events such as pain and sleep (Qu et al., 2006; Urade, 2006; Hayaishi and Urade, 
2002). L-PTGDS is constitutively expressed in the CNS, particularly in the leptomeninges, CP 
from where it is secreted into the CSF, and in oligodendrocytes (Urade et al., 1993; Nagasaka et 
al., 2004). In addition, although not detected normally in macrophages, L-PTGDS was found in 
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macrophages infiltrated in atherosclerotic plaques (Cipollone et al., 2004) and in macrophages 
stimulated with LPS or with Pseudomonas aeruginosa (Joo et al., 2007). However, the regulation 
and significance of L-PTGDS expression in macrophages are unknown. 
In addition to its enzymatic function, L-PTGDS has also been described as an extracellular carrier 
for hydrophobic molecules given its ability to bind, in vitro, retinoic acid, thyroid hormones 
(Tanaka et al., 1997) and gangliosides (Mohri et al., 2006). 
Various studies have investigated if CSF L-PTGDS levels could serve as a potential marker of 
brain disease. No differences were found in different pathological conditions of the CNS such as 
dementia, hydrocephalus, neuropathy, optic neuritis, multiple sclerosis (MS) and demyelinating 
syndrome, when compared to normal individuals; however, the level of L-PTGDS in the CSF 
obtained from patients with brain tumor, was reduced by as much as 2-fold when compared to 
control samples (Saso et al., 1998). Of interest, although the CSF level of L-PTGDS is not 
increased in MS patients, L-PTGDS is increased in the white matter of MS patients, especially in 
plaques (Kagitani-Shimono et al., 2006). In chapter 2 we will discuss the potential implications, 
for the brain, of the increased L-PTGDS we found in the CSF upon a peripheral inflammatory 
stimulus. 
C. Transferrin 
The transferrins are a family of nonheme iron-binding proteins that bind free iron in the blood and 
in other biological fluids. Two major types of transferrins have been described: serum TF and 
lactotransferrin. The principal biological function of transferrins is thought to be related to their iron 
binding properties. Serum TF is responsible for carrying iron from the sites of intake into the 
systemic circulation and then into tissues. Iron delivery to cells occurs via a receptor-mediated 
endocytotic process. TF is synthesized predominantly by hepatocytes, ependymal cells, 
oligodendrocytes and CP epithelial cells and it has been detected in various body fluids including 
plasma, CSF, lymph and breast milk (Zakin et al., 2002). Iron-loaded TF binds to the TFR on the 
cell surface. The TF-TFR complex is internalized and transported to endossomes. In the endossome 
iron is released from TF due to an ATP-dependent protein pump that lowers the pH of the 
endossome and thus facilitates release (Dautry-Varsat, 1986). Inside the cell, iron is delivered to 
various intracellular locations including mitochondria and ferritin (storage). The receptor bound apo-
TF returns to the cell surface where the neutral pH promotes release of apo-TF into the circulation. 
Iron uptake and storage is a well controlled system since while iron is necessary for various vital 
functions, in excess it has deleterious consequences for the cells. Of relevance in iron 
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homeostasis is the observation that free iron in the body promotes the growth of pathogens 
(Teehan et al., 2004). Most bacteria require iron for growth and survival and therefore possess 
mechanisms to acquire iron from the host by: (i) releasing sideropheres that sequester free iron, 
(ii) actively uptaking heme; or (iii) binding holo-transferrin via TFR-like receptors. In response to 
infection, the host up-regulates the synthesis of iron binding proteins, as it is the case for liver 
ferritin (Ceciliani et al., 2002) and macrophages/neutrophils lipocalin 2 (LCN2) (Flo et al., 2004) 
(an iron siderophore to which we will return in chapter 3). In accordance, LCN2 knockout mice 
have increased susceptibility to infections with E. coli and S. aureus (Flo et al., 2004). 
 
All major proteins constitutively expressed by the CP have been somehow implicated in 
peripheral inflammation, which we will further discuss in chapter 2. 
1.2.2.3. The choroid plexus as a first line of brain defence 
The CP can be viewed as a first line in the brain defence against noxious stimulus, whether they 
are molecules, cells or pathogens. The presence of the CP tight junctions prevents the passage 
of several noxious compounds into the CSF. In addition, even for molecules that are taken up by 
the CP epithelial cells, most noxious substances are prevented from entering the CSF because 
the epithelial cells have metabolizing enzymes including Phase I – III enzymes for activation, 
conjugation and transport of drugs. In addition, the CP is able to protect free radical assess into 
the brain parenchyma, given the presence of enzymes such as superoxide dismutase, 
glutathione-s-transferase, and glutathione peroxidase and reductase that protect against free-
radical oxidative stress. 
The CP is also involved in the interaction between the peripheral immune system and the brain. 
Of notice, it has been shown that CP epithelial cells and the CP stroma allow the communication 
between a peripheric inflammatory stimulus and the initiation and development of an innate and 
adaptative response in the brain (Engelhardt et al., 2001). Following systemic activation of the 
immune system by the administration of LPS there is a rapid and transient induction, in the CP, 
of immune-modulators such as Il-1β and Tnf (Quan et al., 1999; Nadeau and Rivest, 1999; 
Marques et al., 2007). Activation of the CP may certainly spread throughout the brain indicating 
that the CP transmits information between the immune system and the brain. Choroidal epithelial 
cells also express major histocompatibility complex class I and class II molecules constitutively 
and inducible, respectively, (Irwin et al., 1999). This observation strongly suggests that the 
epithelial cells can present antigens to T cells in a major histocompatibility complex class II 
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context. Accessory molecules important for leukocyte adhesion such as selectin, lymphocyte (L-
selectin), intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 
(VCAM-1) are found expressed at low levels in CP epithelial cells but can also be up-regulated 
during inflammation (Endo et al., 1998; Wolburg et al., 1999). In a mouse model of infection 
with Streptococcus suis Serotype 2, early transcriptional activation of Toll-like receptor 2 (TLR2), 
CD14, and of inflammatory cytokines in the CP and cells lining the brain endothelium suggests 
that these structures are potential entry sites for bacteria into the CNS (Dominguez-Punaro et al., 
2007). In addition, as the CP is an epithelium, microorganisms such as Neisseria meningitides, 
Trypanosome brucei, and Sendai virus could also have a tropism for CP epithelial cells. 
Despite these various observations, the detailed involvement of the CP in signalling peripheral 
inflammatory stimulus to the brain remains to be elucidated. The work presented in chapters 5 
and 6 intends to further contribute to clarify the CP response to inflammatory challenges induced 
outside the brain. 
1.3. Systemic inflammation induced by lipopolysaccharide 
1.3.1. Lipopolysaccharide 
LPS is a molecular component of the outer membrane of Gram negative bacteria (Alexander and 
Rietschel, 2001; Raetz and Whitfield, 2002). The outer membrane functions as a physical barrier 
that protects bacteria from the surrounding environment and from antibacterial mechanisms. 
LPS is one of the most potent inducers of the immune system and is the principal initiator of the 
septic shock (Elin and Wolff, 1976). 
The use of LPS mimics the inflammation with Gram negative bacteria and for that reason it is 
currently used in experimental models of inflammation. We have chosen this model to study the 
response of the CP to acute and sustained inflammatory challenges. 
1.3.2. Immune response to lipopolysaccharide 
The innate immune response is a universal mechanism of host defence against inflammation 
and infection. It functions on the basis of special receptors called pattern-recognition receptors 
which recognize conserved microbial structures called pathogen-associated molecular patterns. 
TLRs are a group of pattern-recognition receptors that play a crucial role in the recognition of 
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different PAMPs, such as LPS, and in the induction of the immune response (Akira and Hemmi, 
2003; Netea et al., 2004). Cells of the immune system, epithelial cells and endothelium, 
recognize pathogens via TLRs. The signalling cascade downstream of TLR activates pathways 
that culminate with the production of inflammatory cytokines and the development of an immune 
response (Takeda and Akira, 2005). The TLR family comprises different members and it is known 
that TLR4 is responsible for LPS recognition and subsequent responses. However, TLR4 is not 
the sole receptor involved in LPS recognition. Transport of LPS molecules in the serum is 
mediated by LPS-binding protein (Ulevitch and Tobias, 1995). At the plasma membrane, LPS-
binding protein is thought to transfer LPS monomers to CD14, a GPI-linked cell surface protein 
(Ulevitch and Tobias, 1995; Triantafilou and Triantafilou, 2002; Triantafilou and Triantafilou, 
2005). Exactly how CD14 facilitates recognition of LPS by TLR4 is not clear, but its critical role is 
demonstrated by the LPS hyporesponsive phenotype of CD14-deficient mice (Moore et al., 2000; 
Haziot et al., 1996). CD14 is also a co-receptor for TLR2 (Rallabhandi et al., 2006; Remer et al., 
2006; Viriyakosol et al., 2000). Of notice, apart from its well known function as co-receptor for 
TLR-dependent signalling in response to LPS, soluble CD14 can also act as a direct agonist for 
TLR2 (Bsibsi et al., 2007). 
Although TLR2 is able to mediate the LPS response in vitro (Matsuguchi et al., 2000), its role as 
an LPS receptor in vivo has been questioned as a result of the recent findings that gene-
disruption of TLR4 in mice, but not of TLR2, demonstrate phenotypes similar of LPS-
hyporesponsive strains (Hoshino et al., 1999; Takeuchi et al., 1999). 
Once this pathway is triggered it leads to the activation of the transcription factor, nuclear factor 
kappa B (NF-kβ) which regulates the transcription of pro-inflammatory cytokines such as TNF, IL-
1β and IL-6. It can also activate members of the mitogen-activated proteins kinase family (MAPK) 
notably p38 and JUN N-terminal kinase (JNK). These kinases are involved in the transcription of 
genes and they also regulate mRNA stability. 
 
A novel family of DNA binding proteins, referred to as interferon regulatory factors (IRFs) 
(Miyamoto et al., 1988) have been shown to have diverse roles in the regulation of the immune 
system. The involvement of these transcription factors in the innate and adaptative immune 
responses has been gaining more relevance principally because of the discovery that IRFs are 
downstream effectors of the TLR-mediated response (Colonna, 2007; Honda and Taniguchi, 
2006a; Honda and Taniguchi, 2006b). 
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The mammalian IRF family comprises 9 members (Honda and Taniguchi, 2006a) and represents 
an additional molecular pathway in the complex response to LPS. All the members recognize 
sequences in DNA called the IFN-stimulated response element. 
The present concept is that the IRF system governs a broad spectrum of cellular responses in 
immunity (Honda and Taniguchi, 2006a), participating in response to LPS (Barber et al., 1995) 
and as a key pathway in recognition and regulation of the TLR-dependent signalling (Honda and 
Taniguchi, 2006a; Honda and Taniguchi, 2006b; Negishi et al., 2006). The IRF pathway has 
been considered as MyD88 independent but it has already been shown that IRF5 and IRF7 
directly interact with Myd88 and regulate the TLRs-mediated induction of pro-inflammatory 
cytokines (Honda et al., 2005; Uematsu et al., 2005). IRF-1 also interacts with and is activated 
by MyD88 upon TLR activation and when this interaction occurs the migration of IRF-1 into the 
nucleus is more efficiently than non-MyD88 associated IRF-1 (Negishi et al., 2006). 
While LPS has been shown to induce, in the CP, the up-regulation of TLR down-stream genes 
such as IL-1β and TNF, it is still unknown the precise mechanism through which LPS mediates 
the overall CP response to inflammation, which will be further discussed in chapters 5 and 6. 
1.3.3. Systemic inflammation and communication with the brain 
During an immune response the brain and the immune system “talk to each other” and regulate 
each other to maintain body homeostasis. CNS signals the immune system via hormonal and 
neuronal pathways and the immune system signals the CNS mainly through cytokines. The 
precise mechanism by which cytokines act and signal the brain has been the subject of intense 
debate. Peripherally released cytokines can act on the brain via (i) fast transmission pathways 
involving primary afferent neurons of the vagus nerves innervating the site of inflammation; (ii) 
direct entry of cytokines, in small amounts, into the brain through the BBB or BCSFB via a 
saturable transport mechanism, (cytokines are large, hydrophilic proteins and are not expected to 
cross the BBB without a transport system); (iii) interactions within the circumventricular organs, 
for example at the organum vasculosum lamina terminalis or the median eminence and 
(reviewed by Hosoi et al., 2002); (iv) activation of second messengers, such as nitric oxide and 
prostaglandins after binding to receptors at the BBB (Gaillard, 1998) or BCSFB; (v) action of the 
cytokines present in the bloodstream that bind to receptors in endothelial cells of the BBB or the 
epithelial cells of the CP and activate the production of new cytokines. 
Activation of afferent nerve fibers by peripherally released cytokines represents a fast pathway of 
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transmission of immune signals from the periphery to the brain. This pathway sensitizes the 
brain target areas to induce brain-produced cytokines that transmit and amplify the local action of 
peripheral cytokines (reviewed by Hosoi et al., 2002). 
One of the first signals of the actions of cytokines in the brain response is the development of 
fever due to the action of IL-1β (Luheshi, 1998). Additionally, a number of physiological changes, 
known as cytokine-induced sickness behaviour, occur and include anorexia, depressed locomotor 
activity, decreased exploration of the physical and social environment, reduced food and water 
intake, and impaired learning and memory (Dantzer, 2001). Two major mechanisms have been 
evolved in the CNS regulation of the immune system: (a) the hormonal stress response and the 
production of glucocorticoids and (b) the autonomic nervous system with the release of 
noradrenaline. The cytokines in circulation lead to the activation of the hypothalamic-pituitary-
adrenocortical axis ultimately inducing the expression and release of glucocorticoids by the 
adrenal glands. Glucocorticoids regulate the expression of a wide variety of immune molecules, 
including cytokines, adhesion molecules, chemoattractants and molecules involved in immune 
cell trafficking, maturation and differentiation. 
The communication of the peripheral immune system with the brain will be analysed in more 
detail during this dissertation, with specific focus on the participation of the CP. 
1.3.4. Acute-phase response 
The first response of the body to an inflammatory stimulus is the activation of an innate immune 
non-specific response that precedes the specific and adaptative immune reaction. In the innate 
immune response (as is the case of the response to a single injection of LPS) the organism 
develops an acute-phase response and secretes pro-inflammatory cytokines such as IL-1β and 
TNF (Suffredini et al., 1999). The pro-inflammatory cytokines released activate the vascular 
system and inflammatory cells in the circulation. More inflammatory cytokines and other 
inflammatory mediators are produced by these cells and circulate in the blood. 
The cytokines activate receptors on different target cells that respond by altering their metabolism 
and by synthesizing new molecules and proteins. The pattern of protein synthesis by the liver is 
drastically altered resulting in an increase of some blood proteins, globally denominated as 
positive acute-phase proteins, such as C-reactive protein, serum amyloid protein, haptoglobolin, 
and LCN2. The mRNA up-regulation of those proteins is associated with a decrease in the 
synthesis of other normally expressed blood proteins that include TTR, TF, retinol-binding protein, 
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and albumin, therefore designated as negative acute-phase proteins (Ceciliani et al., 2002; 
Gabay and Kushner, 1999; Birch and Schreiber, 1986). 
Other protective mechanisms against invading microorganisms at the hepatic level are the 
induction of heat-shock proteins that function as chaperones for damaged cellular (molecules 
and metallothioneins that increase the hepatic resistance against metal toxicity and may 
enhance the intracellular metal ion binding capacity (Prohaszka, 2003; Borghesi and Lynes, 
1996,. 
 
In the context of response to inflammation, iron seems to be a key player. For that reason we will 
next briefly summarize iron metabolism. 
1.4. Iron homeostasis 
Iron is an essential element for the body homeostasis. Iron deficiencies or excesses can lead to 
pathological conditions such as anemia or hemochromatosis, respectively, and for this reason 
iron metabolism is tightly regulated. The main site of dietary iron absorption is the duodenum. 
Once within the absorptive enterocytes, iron enters a common intracellular pool and is 
subsequently transferred across the basolateral surface of the enterocytes into the bloodstream 
by the iron exporter ferroportin (FPN) (Chua et al., 2007). The released iron is oxidized to ferric 
ion by hephestin, a homolog of the serum ferroxidase ceruloplasmin, and binds to circulating 
plasma TF. TF bound iron is taken up by cells by transferrin receptor 1 (TFR1)-mediated 
endocytosis (Chua et al., 2007). 
The liver, or more specifically the hepatocyte, is the main site of iron deposition and storage 
(Anderson and Frazer, 2005). When the body is iron-replete, macrophages of the liver, spleen, 
and bone marrow also store some of the iron recovered from the phagocytosis of senescent 
erythrocytes. When it is stored, iron is incorporated into ferritin. 
In the bone marrow iron is used for the formation of haemoglobin for the erytrocytes (Figure 3.). 
Most of the body iron (70%) exists in circulation in the erytrocytes, that when these are old or 
damaged are removed from the circulation by macrophages of the reticuloendothelial system. 
Inside the macrophage iron is released from haemoglobin and can either be stored or be 
released back into circulation and bound to TF. 
All this movement of iron, starting in the absorption, is highly regulated and modulated according 
to the iron body requirements and according to the pathological state of the organism. 
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Figure 3. Iron metabolism in the human body. Iron absorption by the enterocyte, transport in the bloodstream bound to transferrin. The 
transferrin-iron complex is taken up by cells for usage or storage. 
 
The uptake of iron is mostly regulated individually by each cell and the expression level of TFR1 is 
regulated by the intracellular level of iron. However, the efflux of iron from the cell seems to be 
systemically regulated by signals and represents the major regulatory point for the maintenance 
of the body iron homeostasis (Frazer and Anderson, 2003). Enterocytes, macrophages and 
hepatocytes are the major cell players in the regulation of iron levels since these are the cells that 
absorb and store higher quantities of iron. 
As an iron exporter, FPN regulates the iron content in circulation; in consequence, the regulation 
of FPN has a central role in iron homeostasis. FPN is under the control of a newly described liver-
derived peptide hepcidin (HAMP) (Krause et al., 2000). Circulating HAMP binds FPN on the 
surface of enterocytes, macrophages and other type of cells causing its internalization and 
degradation. 
Under physiological conditions the level of HAMP is regulated by body iron requirements but 
recently hemochromatosis (HFE), transferrin receptor 2 (TFR2) and hemojuvelin have been 
shown to alter HAMP transcription (Schmidt et al., 2008). HAMP expression can be modulated 
by pro-inflammatory cytokines such as IL-6 and IL-1β during the inflammatory response. The up-
regulation of HAMP was described to be an efficient way to limit iron concentration in circulation 
(Ganz, 2007). The complete mechanism beyond HAMP regulation is, however, still unknown. 
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1.4.1. Iron and innate immunity 
The cells of the immune system are equipped with the machinery capable of regulating iron 
homeostasis through the regulation of several iron genes and proteins (Porto and De Sousa, 
2007). In addition to immune cells, the epithelial cells of the CP, also express genes related to 
iron metabolism and homeostasis, and should therefore be considered in the brain immune 
response. 
In mammalian host, most of the iron is normally bound to various proteins, the hemoproteins, 
ferritina and TF. During innate immune response additional proteins such as LCN2 and 
lactoferrin are increased in various body fluids (Liu and Nilsen-Hamilton, 1995; Sunil et al., 
2007). During evolution pathogens developed highly selective skills for iron uptake. The microbes 
can obtain iron by direct mechanism that requires specific receptors for each iron source, TF, 
lactoferrin, ferritin (Gray-Owen and Schryvers, 1996). Indirect mechanisms are however more 
broadly distributed. Some Gram negative bacteria, for instance, secrete specialized proteins 
called hemophores to acquire heme from different sources (Wandersman and Stojiljkovic, 2000). 
The limitation of this hemophore system is the restriction to heme iron sources that could be 
problematic for pathogens in situations of low heme availability. Another indirect strategy is the 
secretion of other proteins that bind iron from others sources, in analogy to the hemophore 
system. A broad spectrum of prokaryotic and eukaryotic microbes uses small molecule 
compounds called siderophores as high-affinity ferric iron chelators (Miethke and Marahiel, 
2007). These siderophores are secreted by cells during periods of iron starvation. Siderophores 
form extracellular Fe(III) complexes that are then taken up by the pathogen. Inside the cytoplasm 
iron is released from the complex by ferric-siderophore reductases or hydrolases (Miethke and 
Marahiel, 2007). The broad spectrum of microbial mechanisms to acquire iron is the result of 
several constraints made by the host to suppress pathogen multiplication. 
During an acute-phase response the host creates a hypoferremic environment (Laftah et al., 
2006; Fuchs et al., 1991). HAMP is the main mediator of hypoferremia associasted with 
inflammation (Ganz, 2006). Induction of hepcidin by IL-6 and other inflammatory cytokines 
(Nemeth et al., 2004, Kemna et al., 2005, Lee et al., 2005) decreasing the iron uptake in the 
enterocyte. In macrophages, IL-1β and TNF enhance iron storage bound to the ferritin pool 
(Pinero et al., 2000; Laftah et al., 2006). But beyond these basic strategies to create a 
hypoferremic environment, and in response to the mechanisms developed by the pathogens to 
acquire iron, the host has the innate ability to further respond by secreting siderophore-binding 
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proteins as is the case of LCN2 that is able to compete successfully with the high-affinity Fe-
enterobacterin uptake system of enteric bacteria. 
In this dissertation the role of LCN2 and iron in an inflammatory response will be further 
discussed in chapters 3 and 4. 
1.5.  Aims of the study 
The overall objective of this thesis is the study of the CP response to peripheral inflammation. 
Specifically, we intended to: 
− Determine whether the expression of major CP proteins (transthyretin, transferrin and L-
PTGDS) is influenced by an acute inflammatory stimulus induced in the periphery.  
− Elucidate how proteins related to iron metabolism, at the BCSFB, contribute to the innate 
immune response. 
− Investigate whether the CP has an acute-phase response to peripheral inflammation. 
− Establish how the CP responds to a continuous inflammatory stimulus induced in the 
periphery. 
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bstract—Increased interest is being raised on the interac-
ion between systemic inflammation and the brain. The cho-
oid plexus (CP) constitutes a monolayer of epithelial cells
ocated within the brain ventricles and is responsible for the
roduction of cerebrospinal fluid (CSF). Despite the knowl-
dge that the CP capillaries are fenestrated, allowing free
assage of molecules and cells, the involvement of the vast
lood-brain boundary represented by the CP/CSF barrier in
rain inflammatory processes has seldom been considered.
n the present study we investigate, in mice, how the expres-
ion of genes encoding major constitutively expressed CP
roteins is influenced by a systemic inflammatory stimulus.
onfirming that the CP responds to peripheral inflammation,
he messenger RNA (mRNA) levels of the pro-inflammatory
ytokines interleukin 1 beta and tumor necrosis factor alpha
re rapidly induced. As for the constitutively expressed pro-
eins, while the mRNA for genes encoding transthyretin and
ransferrin remain unaltered by the inflammatory challenge,
hat for prostaglandin D2 synthase (LPTGDS) is up-regulated
t 6 h, and stays up-regulated up to 24 h after lipopolysacha-
ide administration. Accordingly, LPTGDS CSF levels are
lso augmented. LPTGDS catalyzes the synthesis of the ma-
or prostanoid of the CNS and, being increased in the CSF,
ight mediate immune signaling into the brain. These obser-
ations emphasize that the CP must be considered a relevant
ediator of immune signals between the periphery and the
rain. © 2006 IBRO. Published by Elsevier Ltd. All rights
eserved.
ey words: inflammation, prostaglandin D2 synthase, trans-
hyretin, cerebrospinal fluid, mice.
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-mail address: japalha@ecsaude.uminho.pt (J. A. Palha).
resented in part in abstract form at the Society for Neuroscience
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bbreviations: BBB, blood-brain barrier; CP, choroid plexus; CSF,
erebrospinal fluid; HPRT, hypoxanthine guanine phosphoribosyl
ransferase; IL-1, interleukin 1 beta; LPS, lipopolysacharide; LPT-
DS, prostaglandin D2 synthase; mRNA, messenger RNA; PCR,
olymerase chain reaction; PGD2, prostaglandin D2; PGH2, prosta-
landin H2; TF, transferrin; TGF-1, transforming growth factor beta 1;
NF-, tumor necrosis factor alpha; TTR, transthyretin; VCAM-1, vas-
12,14r
ular cell adhesion molecule 1; 15d-PGJ2, 15-deoxy- -prostaglan-
in J2.
306-4522/07$30.000.00 © 2006 IBRO. Published by Elsevier Ltd. All rights reser
oi:10.1016/j.neuroscience.2006.09.029
424lthough there is growing evidence of interactions be-
ween systemic inflammation, the brain and neurological
isease (Cunningham et al., 2005), the precise mecha-
isms by which the peripheral immune system transmits
ignals to the brain are largely unknown. While most stud-
es focus on the blood-brain barrier (BBB) (Banks and
astin, 1991; Banks, 2005; Engelhardt and Ransohoff,
005; Engelhardt, 2006), a less investigated pathway of
ommunication involves the choroid plexus (CP)/cerebro-
pinal fluid (CSF) route.
The CP is an epithelial cell monolayer located within
he brain ventricles, responsible for the production of at
east two-thirds of the CSF (Speake et al., 2001). By filling
ll brain ventricles and the subarachnoid space, the CSF is
n contact with a vast region of the brain parenchyma.
espite the knowledge that blood flow through the CP is up
o 10 times higher than in other brain regions, and that the
P membrane surface area is of the same order of mag-
itude as that formed by the BBB (Keep and Jones, 1990),
ew studies address the CP participation in brain inflam-
atory processes. In addition to producing CSF, the CP is
lso an active site of protein synthesis and possesses
arious relevant receptors in the inflammatory process,
ncluding that for the bacterial lipopolysacharide (LPS) (La-
roix et al., 1998) and several others for neurotransmitters,
rowth factors and hormones (Chodobski and Szmydyn-
er-Chodobska, 2001). Therefore, the CP seems singu-
arly well equipped to function in the surveillance and main-
enance of the biochemical milieu of the CNS under both
hysiological and pathological conditions (Chodobski and
zmydynger-Chodobska, 2001) including inflammation.
urthermore, recent studies implicated CP proteins (trans-
hyretin [TTR], the major protein synthesized and secreted
y the CP, and the receptor megalin) as neuroprotective in
lzheimer’s disease (Carro et al., 2005a; Carro et al.,
005b; Sousa et al., 2006).
One other finding indicating that the CP could have a
ritical role as a “mediator” of the interactions between the
NS and the peripheral immune system is the migration of
ymphocytes from the blood to the apical side of the CP
pithelia (Petito and Adkins, 2005), a process facilitated by
he expression of adhesion molecules (Endo et al., 1998;
olburg et al., 1999; Engelhardt et al., 2001). The CP has
lso been suggested as a route for virus (such as human
mmunodeficiency virus) access into the brain (Petito,
004).
Collectively these observations strongly suggest that
he CP could act as a brain “immune sensor” involved in
he communication of the immune system with the CNS. Of
elevance, it is unknown whether the inflammation often
ved.
a
C
c
z
h
t
g
A
A
m
E
f
m
a
1
r
l
t
t
5
S
m
w
F
r
i
D
(
e
c
m
t
n
e
G
T
b
(
s
s
r
i
a
c
5
u
n
t
g
g
a
G
n
s
i
g
v
U
E
p
1
(
q
r
(
e
m
D
t
c
a
I
c
G
i
L
5
p
(
d
A
o
n
w
f
a
n
r
p
B
i
S
V
d
n
C
t
T
w
p
c
p
p
s
2
I
e
p
2
(
c
L
l
a
t
F. Marques et al. / Neuroscience 144 (2007) 424–430 425ssociated with neurological diseases could influence the
P/CSF barrier properties and/or affect decisively pharma-
ological treatment strategies (Johanson et al., 2005; Stra-
ielle and Ghersi-Egea, 2005). In order to further study
ow the CP responds to a systemic inflammatory stimulus,
he present study evaluates, over time, the expression of
enes encoding major CP proteins.
EXPERIMENTAL PROCEDURES
nimals and LPS injection
ll experiments were conducted using 8–9 week C57BL/6 male
ice (Charles River, Barcelona, Spain), in accordance with the
uropean Communities Council Directive 86/09/EEC guidelines
or the care and handling of laboratory animals. All efforts were
ade to minimize animal suffering and reduce the number of
nimals used in these studies. Animals were maintained under a
2-h light/dark cycle at 22.5 °C and 55% humidity and fed with
egular rodent chow (Mucedola, Milano, Italy) and tap water ad
ibitum. In order to reduce stress-induced changes in the hypo-
halamus-pituitary axis, animals were handled for 1 week prior to
he beginning of the experiment. Animals were injected i.p. with
g/g body weight of LPS (Escherichia coli, serotype O55:B5;
igma, St. Louis, MO, USA) or vehicle alone (0.9% NaCl).
Animals were anesthetized with ketamine hydrochloride (150
g/kg) plus medetomidine (0.3 mg/kg), transcardially perfused
ith cold saline and killed 1, 3, 6, 12, 24 or 72 h after LPS injection.
or messenger RNA (mRNA) studies, liver and CP were rapidly
emoved, frozen in liquid nitrogen and stored at 80 °C. CP
solation was made under conventional light microscopy (Stemi
V4, Carl Zeiss, Oberkochen, Germany). At least five pools of CP
from four animals each) were prepared for each time point. The
xperiment was done twice. In another experiment, CSF was
ollected from the cisterna magna and pooled from several ani-
als. An aliquot was kept for blood contamination analysis, and
he remainder immediately frozen. No samples were contami-
ated, in accordance with the criteria previously described (Huang
t al., 1995).
ene expression analysis
otal RNA, isolated from liver using Trizol (Invitrogen, Carls-
ad, CA, USA) and from CP using the RNAqueous-Micro Kit
Ambion, Austin, TX, USA), was reverse transcribed into first-
trand complementary DNA using the superscript first-strand
ynthesis system for reverse-transcription polymerase chain
eaction (PCR) (Invitrogen) according to the manufacturer’s
nstructions. Semiquantitative multiplex PCRs were performed
s previously described (Wong et al., 1994). Briefly, each PCR
ycle was composed of the following steps: 94 °C for 30 s,
8 °C for 45 s, and 72 °C for 60 s. A sequential series of PCRs
sing each primer pair was performed initially to determine the
umber of cycles in which the amplification would reside within
he exponential phase of the amplification curve both for the
ene under study and for the housekeeping gene hypoxanthine
uanine phosphoribosyl transferase (Hprt) (gene abbreviations
nd gene names are specified in accordance with the HUGO
ene Nomenclature Committee at http://www.gene.ucl.ac.uk/
omenclature/). The expression level of Hprt was used as internal
tandard, to which other PCR amplification products were normal-
zed. Aliquots of the PCR products were separated by 2% agarose
el electrophoresis and stained with ethidium bromide. Gels were
isualized with AlphaImager 2200 (AlphaInnotech, San Leandro, CA,
SA) and analyzed densitometrically with the corresponding Alpha-
ase software. The oligonucleotide primers for (Ttr, transferrin (Tf),
rostaglandin D2 synthase (Lptgds), transforming growth factor beta
(Tgf-1), and Hprt were designed using the Primer3 software rRozen and Skaletsky, 2000) on the basis of the GenBank se-
uences: NM013697; NM133977; NM008963; M13177; XM356404,
espectively.
For interleukin 1 beta (Il-1) and tumor necrosis factor alpha
Tnf-), genes routinely studied in the laboratory, expression lev-
ls were studied by real-time PCR using the LightCycler instru-
ent (Roche, Indianapolis, IN, USA). The LightCycler-FastStart
NA Master Hybridization Probes mixture was used according to
he manufacturer’s instructions. The cycling parameters were 1
ycle of 95 °C for 10 min, followed by 45 cycles of 94 °C for 10 s,
nnealing temperature (60 °C for Hprt and Tnf- and 57 °C for
l-1) for 10 s and 72 °C for 11 s. The specific probes for each
ytokine were designed and synthesized by TIB MolBiol (Berlin,
ermany). Single acquisition was done at the end of each anneal-
ng step. All primer sequences are available on request.
PTGDS and TNF- determinations
l CSF or serum (negative control) were run on 15% SDS-
olyacrylamide gel and transferred onto nitrocellulose membrane
Amersham Biosciences, Piscataway, NJ, USA). LPTGDS was
etected using a polyclonal antibody (Cayman Chemical, Ann
rbor, MI, USA) at 1:1000 dilution, followed by a secondary per-
xidase-conjugated goat anti-rabbit antibody (Santa Cruz Biotech-
ology, Santa Cruz, CA, USA) at 1:10000 dilution, and developed
ith the chemiluminescence system (Pierce Biotechnology, Rock-
ord, IL, USA). Autoradiographs were scanned for densitometry
nalysis using a computerized image analysis system (AlphaIn-
otech, San Leandro, CA, USA; AlphaEase software). Data are
eported as densitometry units.
TNF- levels were determined in 50 l serum and 10 l
ooled CSF samples using BDTM cytometric bead array (BD
iosciences, San Jose, CA, USA) according to the manufacturer’s
nstructions.
tatistical analysis
alues are reported as meanS.E. Statistical significance was
etermined using Student’s t-test and nonparametric Mann-Whit-
ey test, with differences considered significant at P0.05.
RESULTS
horoid plexus and liver gene expression response
o peripheral inflammation
o confirm that an acute-phase inflammatory response
as properly elicited, we measured, in the liver, the ex-
ression levels of Il-1 and Tnf-, two pro-inflammatory
ytokines, at different time points. As expected, the ex-
ression of both genes is up-regulated by LPS. The ex-
ression of Il-1 and Tnf- peaks at 1 h and remains
ignificantly elevated at 12 h, returning to basal levels at
4 h (Fig. 1a and c, respectively) after LPS injection.
nterestingly, liver Tgf-1 (an anti-inflammatory cytokine)
xpression levels are significantly higher at 3 h (when the
ro-inflammatory response starts to decrease), peak at
4 h, and at 72 h are still higher compared to controls
Fig. 1e).
CP expression of Il-1 is not detected under basal
onditions but is strongly elicited 1 h after injection of
PS, remaining detectable 72 h after (Fig. 1 b). Simi-
arly, Tnf- (Fig. 1d) is not detected in saline injected
nimals, peaks at 1h and at 72 h after LPS administra-
ion is still detectable. Tgf-1 up-regulation never
eaches statistical significance when compared with the
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F. Marques et al. / Neuroscience 144 (2007) 424–430426asal level, but it is slightly and consistently up-regu-
ated from 3 h up to 24 h (Fig. 1f).
We next investigated whether the expression of con-
titutive major CP proteins are influenced by an inflamma-
ory stimulus and, when applicable, how this relates to the
iver response. While the liver expression of Ttr is statisti-
ally significantly decreased from 6 h to 24 h (Fig. 2a), its
evels in the CP decrease slightly and consistently without
eaching statistical significance when compared with basal
xpression (Fig. 2 b). Similarly, Tf liver levels are de-
reased at 3 h (Fig. 2c) but unaltered in the CP for the time
ourse of the experiment (Fig. 2d). In contrast, the expres-
ion of Lptgds is significantly increased from 6 h to 24 h
nd returns to basal levels at 72 h after LPS injection (Fig.
ig. 1. mRNA expression kinetic profile of CP and liver cytokines up
p-regulated 1 h after LPS injection, and return gradually to the basal
or Tnf- expression (c, d). The expression of Tgf-1 is significantly up-r
p-regulated without reaching statistical significance.e). Lptgds is not expressed in the liver. tPTGDS and TNF- determination
he increased mRNA expression levels of cytokines and
PTGDS correlate with the increase in protein concentra-
ion. 1 h after LPS injection, TNF- serum (n3) and CSF
n3) levels increase from 14.30.1 to 2622121 and
rom below detection to 12312 pg/ml, respectively; and
ecay almost to normal levels after 12 h (Fig. 3a). As seen
n Fig. 3b, CSF LPTGDS concentration increases about
0% when compared with basal conditions at 12 and 24 h
fter the inflammatory stimulus.
DISCUSSION
y measuring the expression levels of several CP genes,
induced systemic inflammation. Liver (a) and CP (b) Il-1 levels are
saline-injected animals 72 h later. A similar kinetic profile is observed
in the liver (e) from 3 h up to 72 h, while in the CP (f) it is only modestlyon LPS-
levels of
egulatedhe present study clearly shows that the CP responds
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F. Marques et al. / Neuroscience 144 (2007) 424–430 427romptly to a peripheral inflammatory stimulus. Such re-
ponse includes not only genes encoding well-described
mmune modulators such as Il-1 and Tnf-, but also
enes encoding major constitutively expressed CP pro-
eins such as LPTGDS. Of relevance, this effect on the CP
s reflected in the CSF composition, as suggested by the
ncreased CSF levels of TNF- and LPTGDS.
We show here, for the first time, that the expression of
ptgds is up-regulated at 6, 12 and 24 h after the inflam-
atory stimulus, returning to basal levels at 72 h. Accord-
ngly, CSF LPTGDS levels increase, which is in agreement
ith the kinetic profile of increased CSF concentration
eported in rats after i.p. injection of LPS (Ishizaka et al.,
001). Lptgds is constitutively highly expressed by the CP
Blodorn et al., 1996), from which it is secreted into the
SF, and also by oligodendrocytes (Urade et al., 1993;
ig. 2. CP and liver mRNA expression kinetic profile of proteins const
to 24 h after LPS administration and those of TF (c) decrease at 6
espectively). The expression of Lptgds, which is absent in the liver, iagasaka et al., 2004). LPTGDS catalyzes the isomera- mion of prostaglandin H2 (PGH2) to produce prostaglandin
2 (PGD2), the major prostanoid in the CNS. The up-
egulation of Lptgds might be secondary to the increase of
L-1 since the latter induces the expression of cyclooxy-
enase 2, an enzyme upstream in the prostaglandin path-
ay (Fujimori et al., 2003), as recently shown by the en-
anced expression of spinal cord Lptgds and PGD2 bio-
ynthesis during systemic inflammation (Grill et al., 2006).
hether directly or indirectly stimulated, a quick and tran-
ient increase in Lptgds expression in response to an
nflammatory stimulus might be sufficient to induce second
essenger signals to the brain parenchyma. PGD2, like
ther prostagladins, has been implicated as mediating
oth pro- and anti-inflammatory actions (Harris et al., 2002;
rade and Hayaishi, 2000). Recent studies showed, for
nstance, that PGD2 mediates neuroinflammation and de-
xpressed by the CP. TTR mRNA levels in the liver (a) decrease from
the expression of both genes is not influenced in the CP (b and d,
antly increased in CP (e) from 6 to 24 h.itutively e
h, whileyelination in twitcher mice (Mohri et al., 2006). On the
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F. Marques et al. / Neuroscience 144 (2007) 424–430428ther hand, endogenous PGD2 might display anti-inflam-
atory properties, given its ready conversion to bioactive
yclopentenone-type prostaglandins of the J2-series such
s 15-deoxy-12,14-prostaglandin J2 (15d-PGJ2) (Arm-
trong, 1996; Straus and Glass, 2001; Mouihate et al.,
004). 15-dPGJ2 displays anti-inflammatory properties by
epressing the expression of genes encoding inflammatory
olecules such as inducible nitric oxide synthase and
nf- (Jiang et al., 1998; Ricote et al., 1998; Rossi et al.,
000; Straus et al., 2000), attenuates immune activation of
everal pro-inflammatory molecules in various culture sys-
ems and has antipyretic properties (Mouihate et al., 2004).
owever, in specific circumstances, 15d-PGJ2 also has
ro-inflammatory properties (Harris et al., 2002). Of notice,
ncreased immunoreactivity against vascular cell adhesion
olecule 1 (VCAM-1) and major histocompatibility com-
lex antigens in the apical site of the CP epithelium (En-
elhardt et al., 2001) is observed in conditions of brain
nflammation such as those in experimental autoimmune
ncephalitis, which might contribute to activation of intra-
entricular T lymphocytes. If so, the up-regulation of CP
ptgds we observe starting at 6 h after LPS stimulus could
lso contribute to the resolution of inflammation by down-
egulating the expression of VCAM-1, as recently shown in
ndothelial cells with increased endogenous PGD2 levels
Negoro et al., 2005).
Since some of the CP major proteins are also synthe-
ized by the liver, we could compare the liver and CP
cute-phase responses to inflammation. Both the liver and
he CP respond to LPS by quickly inducing the expression
f the pro-inflammatory cytokine Il-1 and Tnf- genes.
nterestingly, the up-regulatory kinetic profile is similar in
oth tissues, peaking at 1 h and returning to basal levels
but still detectable in the case of the CP) at 72 h. Although
P Il-1 and Tnf- expression has never been investi-
ig. 3. TNF- and LPTGDS levels. CSF and serum TNF- levels dr
evels of CSF LPTGDS increase about 50% at 12 and 24 h after theated or discussed, per se, in the context of inflammation, 2revious in situ hybridization studies have shown an iden-
ical kinetic profile for both genes after peripheral LPS
dministration (Quan et al., 1998; Nadeau and Rivest,
999). Altered gene expression in the CP might ultimately
nfluence CSF composition. While other sources may con-
ribute to increased CSF cytokine concentration upon an
nflammatory stimulus in the periphery, it is reasonable to
uggest that the CP greatly contributes to it. Accordingly,
he increase in TNF- levels we find in the CSF correlates
ith the CP expression profile.
Up-regulation of anti-inflammatory cytokines in the
iver, such as Tgf-1, occurs by the time the inflammatory
esponse starts to decrease, as we see here at 3 h after
ndotoxin administration. Interestingly, a similar increase
s observed for the CP from 3 h up to 72 h, even though the
ifference from basal levels does not reach statistical sig-
ificance. To our knowledge, no studies to date have ad-
ressed Tgf-1 expression in the CP under systemic in-
ammatory conditions. The slight but consistent increase
n expression of CP Tgf-1 we show here might constitute
n attempt to control the inflammatory response triggered
n the CP. Indeed, TGF-1 blocks proliferation and sup-
resses functions of activated microglia (Bottner et al.,
999). Notably, the CP also produces the receptors for
GF-1 and IL-1 (Chodobski and Szmydynger-Chodob-
ka, 2001). Therefore, even a slight change in IL-1 and
GF-1 production might regulate the synthesis and se-
retion of other choroidal proteins via autocrine/paracrine
ignaling, a possibility that deserves further study.
In the present study we also analyzed the expression
f two other major CP proteins: TTR (Aldred et al., 1995)
nd TF. As carriers for amyloid beta peptide and iron,
espectively, both have recently been implicated in neuro-
ogical diseases such as Alzheimer’s disease (Palha,
002; Zecca et al., 2004; Carro et al., 2005a; Carro et al.,
ncrease 1 h after LPS injection, rapidly returning to basal levels (a).
al inflammatory stimulus is imposed (b). OD, optical density.005b; Sousa et al., 2006). A single report implicates TTR
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F. Marques et al. / Neuroscience 144 (2007) 424–430 429s an endogenous anti-inflammatory mediator given its
bility, in vitro, to inhibit monocyte and endothelial IL-1
roduction (Borish et al., 1992). While TTR is a negative
cute phase protein in the liver (Birch and Schreiber,
986), s.c. injection of turpentine did not influence CP Ttr
xpression (Dickson et al., 1986). We also find that up to
2 h after i.p. injection, LPS administration does not influ-
nce CP Ttr expression; even though Ttr expression de-
reases in the liver from 6h up to 24h after injection.
imilarly, the mRNA for TF, another liver negative acute
hase protein, decreases after LPS administration; but no
ffect is observed in its CP expression. The differential
esponse in the liver when compared with the CP possibly
esults from tissue-specific transcription factors influencing
tr (Costa et al., 1990; Yan et al., 1990) and Tf (Zakin et
l., 2002) transcription regulation, as previously sug-
ested. The expression of cystatin C and insulin growth
actor 2, two other proteins constitutively expressed by the
P, are not influenced by the inflammatory challenge used
n this study (data not shown).
In summary, by influencing the expression of both pro-
nd anti-inflammatory molecules, the CP seems to behave
s an immunosensor for the brain. Studying the detailed
alance between both types of signals is certainly essen-
ial to understand the final response of the brain to an
nflammatory insult, and the CP must be considered a
elevant player in such processes.
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Brief Communication
Lipocalin 2 is a choroid plexus acute-phase protein
Fernanda Marques1, Ana-Joa˜o Rodrigues1, Joa˜o C Sousa1, Giovanni Coppola2,
Daniel H Geschwind2, Nuno Sousa1, Margarida Correia-Neves1 and Joana A Palha1
1Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus
Gualtar, Braga, Portugal; 2Program in Neurogenetics, Department of Neurology, David Geffen School of
Medicine, University of California Los Angeles, Los Angeles, California, USA
Lipocalin 2 (LCN2) is able to sequester iron-loaded bacterial siderophores and, therefore, is known
to participate in the mammalian innate immune response. Of notice, LCN2 was shown to display
bacteriostatic effects both in in vitro and in vivo. To reach the brain, bacteria must cross the blood–
brain or the choroid plexus (CP)/cerebrospinal fluid (CSF) barriers. Additionally, as the CP is
responsible for the production of most of the CSF, responses of the CP mediate signaling into the
brain. We show here that in conditions of peripheral inflammation, LCN2 behaves as an acute phase
protein in the CP. As early as 1 h after lipopolysaccharide peripheral administration, Lcn2 mRNA
levels are upregulated, returning to basal levels after 72 h. Increased LCN2 protein is observed in
choroidal epithelia and in endothelial cells of blood vessels in the brain parenchyma. Higher levels
of LCN2 are also present in the CSF. These observations suggest that expression of LCN2 at the
CP/CSF barrier might be bacteriostatic in the brain, avoiding bacteria dissemination within the CSF
into the brain parenchyma. This study shows that the LCN2 is produced by the CP as a component
of the innate immune response that protects the central nervous system from infection.
Journal of Cerebral Blood Flow & Metabolism advance online publication, 26 September 2007; doi:10.1038/sj.jcbfm.9600557
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Introduction
The brain is protected from the periphery by the
blood–brain and blood–cerebrospinal fluid (CSF)
barriers. These barriers restrict the passage of several
endogenous and xenobiotic compounds from the
periphery to the central nervous system. Although
most studies focus on the blood–brain barrier,
evidence is increasing on the role of the choroid
plexus (CP) in communication between the immune
system and the central nervous system. The CP is
located within the brain ventricles, and its epithelial
cells are responsible for producing most of the CSF.
In addition to producing CSF, the CP is also an
active site of protein synthesis and possesses
receptors for several immune mediators, hormones,
and growth factors (Chodobski and Szmydynger-
Chodobska, 2001). Therefore, anatomically and
physiologically, the CP is well positioned to respond
to stimulus induced in the periphery. Unraveling
which are the molecular mediators of the CP
response to inflammation and infection is, therefore,
important to understand how the CP mediates or
protects the brain from associated brain damage.
The Gram-negative bacteria lipopolysaccharide
(LPS), a major molecular component of the cell
wall, has been widely used as a model of inflamma-
tion and as a tool to study response to infection.
Cells of the immune system are able to recognize
LPS through the Toll-like receptors (TLRs), which
induce signals responsible for the activation of the
innate immune response. One of the proteins shown
previously to participate in such a response is
lipocalin 2 (LCN2). Lipocalin 2, a member of the
lipocalin family of proteins, was initially found in
neutrophil granules (Kjeldsen et al, 2000) and later
described as an acute-phase protein in the liver (Liu
and Nilsen-Hamilton, 1995; Sunil et al, 2007), in
blood and peritoneal cells (Flo et al, 2004), and in
several epithelial tissues (Cowland et al, 2003).
Lipocalin 2 binds to the iron-loaded siderophores,
iron chelators secreted by pathogens, and represents
an effective defense strategy for the body to control
the growth of pathogens (Neilands, 1995). By limit-
ing iron availability, LCN2 exerts a bacteriostatic
effect as shown both in in vitro (Goetz et al, 2002)Received 5 July 2007; revised and accepted 23 August 2007
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and in vivo (Flo et al, 2004). Thus, limitation of iron
availability is a very effective defense strategy for
the body to control the growth of pathogens.
In this study, we intended to investigate whether
the LCN2 was among the immune modulators
induced in the CP in response to peripheral
inflammation.
Materials and methods
Animals and Lipopolysaccharide Injection
All experiments were conducted using 8- to 9-week-old
C57BL/6 male mice (Charles River, Barcelona, Spain), in
accordance with the European Community Council
Directive 86/09/EEC guidelines for the care and handling
of laboratory animals. Animals were maintained under
12 h light/dark cycles at 22 to 241C and 55% humidity and
fed with regular rodent’s chow and tap water ad libitum.
To reduce stress-induced changes in hypothalamus–
pituitary axis associated with the injection, animals were
handled for 1 week before the beginning of the experi-
ment. Animals were administered LPS intraperitoneally at
a 5 mg/g body weight dose (Escherichia coli, serotype
O26:B6; Sigma, St Louis, USA); a subset of animals was
injected with vehicle (0.9% NaCl) alone.
Animals were anesthetized with ketamine hydrochlor-
ide (150 mg/kg) plus medetomidine (0.3 mg/kg), transcar-
dially perfused with cold saline, and killed 1, 3, 6, 12, 24,
or 72 h after LPS injection. For the mRNA studies, CP
isolation was made under conventional light microscopy
(SZX7; Olympus, Hamburg, Germany), and tissue was
rapidly removed, frozen in dry ice, and stored at 801C. At
least five pools of CP (from three animals each) were
prepared for each time point. The experiment was
performed twice. Cerebrospinal fluid was collected from
the cisterna magna and pooled from several animals. An
aliquot of each pool was used to verify the absence of
blood contamination and the remainder was immediately
frozen.
Quantitative PCR Lipocalin 2 Gene Expression
Measurements
Total RNA was isolated from CP using Trizol reagent
(Invitrogen, Carlsbad, CA, USA). 500 ng of total RNA were
amplified using the Superscript RNA amplification sys-
tem (Invitrogen) according to the manufacturer’s instruc-
tions. Choroid plexus RNA was reverse transcribed using
random primers of the superscript first-strand synthesis
system for reverse transcription PCR (Invitrogen).
Quantitative real-time PCR analysis was used to
measure the expression levels of the Lcn2 mRNA
transcript. The reference gene, hypoxanthine guanine
phosphoribosyl transferase (Hprt), was used as internal
standard for normalization (gene abbreviations and gene
names are specified in accordance with the HUGO Gene
Nomenclature Committee at http://www.gene.ucl.ac.uk/
nomenclature/), since we have first confirmed that its
expression is not influenced by the experimental condi-
tions.
The oligonucleotide primers for Lcn2 and Hprt were
designed using the Primer3 software on the basis of the
GenBank sequences NM_008491 and NM_013556, respec-
tively. The real-time PCR reactions, using equal amounts
of total RNA from each sample, were performed on a
LightCycler instrument (Roche Diagnostics, Basel, Swit-
zerland) using QuantiTect SYBR Green RT-PCR reagent kit
(Qiagen, Hamburg, Germany). Product fluorescence was
detected at the end of the elongation cycle. All melting
curves exhibited a single sharp peak at a temperature
characteristic of the primer used.
Immunohistochemistry
Animals were transcardially perfused, under anesthesia,
with 4% of paraformaldehyde in phosphate-buffered
saline, 12 and 24 h after LPS or saline injections. After
perfusion, brains were removed from the skull, left 24 h in
the fixative solution, and then included in paraffin.
Immunohistochemistry was performed on coronal sec-
tions (10 mm) with anti-mouse lipocalin-2/neutrophil
gelatinase-associated lipocalin (R&D Systems, Minneapolis,
MN, USA) at 1:500 dilution or anti-transthyretin (kindly
provided by Dr MJ Saraiva, Institute for Molecular and
Cell Biology, Porto, Portugal) at 1:1,000 dilution as
primary antibodies. Secondary antibodies, biotinylated
(Vector Laboratories Inc., Burlingame, CA, USA) or
fluorescent (Molecular Probes, Carlsbad, CA, USA) were
used at 1:200 and 1:500, respectively, following standard
procedures. For this analysis, we used three animals per
group. Samples were analyzed using optical (BX61;
Olympus) or confocal (FV1000; Olympus) microscopes.
Protein Measurements
For the detection of LCN2 protein in the CSF, we
performed a direct enzyme-linked immunosorbent assay.
Two microliters of CSF was used to detect LCN2 levels at
the different time points. Lipocalin 2 was detected using
the same antibody mentioned above, at 1:300 dilution,
followed by a secondary peroxidase-conjugated donkey
anti-goat antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) at 1:500 dilution, and developed with 2-20azino-
bis (3-ethylbenzthiazoline-6-sulphonic acid) diammo-
nium salt (ABTS) (Sigma). The reaction was stopped
using 0.1 mol/L citric acid and read at an optical density of
405 nm. The standard curve was made with the recombi-
nant mouse LCN2/neutrophil gelatinase-associated lipo-
calin (R&D Systems). The detection limit was 50 ng/mL.
Statistical Analysis
Values are reported as mean7s.e. Statistical significance
was determined using the non-parametric Mann–Whitney
test, with differences considered significant at P < 0.05.
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Results
Lipocalin 2 Expression Profile in Choroid Plexus and
Cerebrospinal Fluid Levels after Lipopolysaccharide
Injection
Choroid plexus Lcn2 expression was very low in
basal conditions (and identical at any time point
after saline injection), but strongly upregulated from
1 to 72 h after LPS injection, with a peak at 12 h
(Figure 1A). In the CSF, LCN2 was below detection
level in basal conditions until 3 h after LPS injection
(Figure 1B). A robust upregulation was observed at
6 h, remained for at least 24 h and returned to basal
levels at 72 h after LPS administration. The same
expression profile was observed in the liver (data
not shown). Increased expression of Lcn2 in the CP
preceded the increase in the CSF protein, suggesting
that LCN2 is produced and secreted by epithelial CP
cells to the CSF.
Immunohistochemistry Analysis
We next studied, by immunohistochemistry, the
LCN2 protein immunoreactivity in the CP. As shown
in Figure 2, although no signal was observed in
saline controls (Figures 2A, 2D and 2G) at 12 h (or at
any time point after saline injection), at 12 h after
LPS administration immuno-positive staining was
observed in CP epithelial cells but also in other cells
within the CP stroma (Figures 2B and 2E); staining
was also observed in endothelial cells throughout
the brain parenchyma (Figure 2H). At 24 h, staining
was mostly observed in CP epithelial cells (Figures
2C and 2F). In the endothelial cells of the brain
parenchyma, a weaker staining was still observed
(Figure 2I). Of notice, not all CP epithelial cells
showed labeling for LCN2. Double staining for LCN2
and transthyretin, a protein specifically synthesized
by CP epithelial cells, confirmed that LCN2 is
produced by epithelial cells of the CP (Figure 2J).
Discussion
Although an acute-phase response is well described
for the liver, increased evidence is supporting a
similar response at the blood–brain barriers (Mar-
ques et al, 2007; Quan et al, 1998). This study
shows, in vivo, that the gene encoding for LCN2 is
quickly upregulated in the CP in response to a
peripheral immune challenge. As a result, increased
levels of LCN2 are secreted into the CSF. Similarly,
increased LCN2 is also observed in blood vessels of
the brain parenchyma. Because LCN2 binds to
various iron-loaded bacterial siderophores, this
increase in LCN2 levels is expected to decrease iron
availability for bacterial growth and, therefore, may
constitute an important mechanism of neuroprotec-
tion against bacteria accessing and disseminating
within the brain.
While reporting the blood–brain and blood–CSF
barriers as novel sites of LCN2 synthesis, we confirm
liver upregulation of Lcn2 mRNA after an LPS
inflammatory challenge with a profile similar to
that just recently reported (Sunil et al, 2007).
Within the CP, immunohistochemistry reveals
positive labeling for LCN2 in epithelial cells only
in LPS-treated animals. Interestingly, not all CP
epithelial cells are immunoreactive to LCN2 anti-
bodies, suggesting that only certain cells express
LCN2 in detectable amounts, at least at a given time.
Staining is also observed in blood vessels in the
brain parenchyma. It is likely that the other cells of
the CP stroma immuno-positive for LCN2 are also
endothelial cells of the CP vasculature. These
observations together with the fact that endothelial
cells of the CP capillaries are fenestrated, and that
LCN2 also increases in the blood upon an inflam-
matory stimulus (Flo et al, 2004) might be particu-
larly relevant in impeding pathogen access into the
brain. On one hand, LCN2 might reduce iron access
to the bacteria in the blood vessels and, in the case
of bacteria entering into the CSF, CSF-borne LCN2
can sequester siderophore-bound iron and prevent
bacteria dissemination within the ventricular brain
system and into the brain parenchyma. Of notice, it
has been recently reported that human neutrophil
gelatinase-associated lipocalin, the human homolog
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Figure 1 Lipocalin 2 (Lcn2) mRNA expression in the choroid
plexus and LCN2 cerebrospinal fluid (CSF) levels are increased
in mice injected with lipopolysaccharide (LPS). (A) Lcn2
expression is strongly induced by peripheral administration of
LPS, peaking at 12 h and returning to basal levels after 72 h.
(B) This increase in Lcn2 expression results in augmented
circulating CSF LCN2 protein levels, observed from 6 until 24 h
after LPS injection. b.d., below detection.
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of LCN2, is taken up by cells through the receptor
megalin (Hvidberg et al, 2005). Since megalin is a
scavenger receptor present in the CP and in the
endothelial cells of blood vessels, it is possible that
neutrophil gelatinase-associated lipocalin bound
to iron-loaded siderophore can be taken up by
these cells, further preventing iron availability for
bacterial growth within the CSF and the brain
parenchyma.
This is, to the best of our knowledge, the first
demonstration of LCN2 synthesis at the blood–brain
barriers in vivo. Previous studies failed to show Lcn2
mRNA in whole brain extracts or several regions of
the brain parenchyma (Cowland et al, 2003) under
Figure 2 Immunohistochemistry for lipocalin 2 (LCN2) in the choroid plexus (CP) and in blood vessels of the brain parenchyma of
mice injected with lipopolysaccharide (LPS). Although no staining is present in (A, D, and G) saline controls, LCN2-positive cells are
observed (B, E, and H) 12 h and (C, F, and I) 24 h after LPS injection. At 12 h, positive staining is observed not only in epithelial cells
(arrow) but also in other cells of the (B and E) CP stroma (star), as well as in endothelial cells of blood vessels in the (H) brain
parenchyma. In the CP, at 24 h staining seems restricted to (C and F) epithelial cells, and a weaker staining is still present in the (I)
blood vessels. Staining for (J) transthyretin, a marker of CP epithelial cells, confirms the presence of LCN2 in epithelial cells. Scale
bar = (A–C) 100; (D–F) 20; (G–I) 50, and (J) 10mm.
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normal physiological conditions. On the contrary,
two other studies have previously reported upregu-
lation of LCN2 expression in whole brain extracts by
turpentine (Liu and Nilsen-Hamilton, 1995) and in
the basal forebrain of mice intranasally infected
with influenza virus (Ding and Toth, 2006). Given
this data, it is likely that Lcn2 expression in the CP
and in blood vessels is contributing to the overall
upregulation of Lcn2 expression observed in whole
brain homogenates, particularly since some of these
brain regions are often contaminated by CP tissue
(Sousa et al, 2007). Of notice, a recent report using
LPS stimulation of primary cultures enriched in CP
epithelial cells showed induction of LCN2 secretion,
which is in agreement with the in vivo data we
report here (Thouvenot et al, 2006).
Still to investigate is the molecular pathway that
triggers LCN2 expression at these sites. In vitro
studies in a lung epithelial cell line stimulated by
interleukin-1b (IL-1b) showed upregulation of
LCN2, whereas LPS did not (Cowland et al, 2006).
It is possible that IL-1b produced in the periphery in
response to LPS induces a response in the CP and in
blood vessels through IL-1b receptors (Cunningham
et al, 1992). This would induce the synthesis of
additional IL-1b and other immune mediators, such
as LCN2. Alternatively, or in addition, the response
might be directly linked to activation of receptors to
bacterial endotoxins located at the barriers, as has
been shown in vitro for LPS activation of LCN2
expression in macrophages (Meheus et al, 1993) and
in lung epithelial cell lines transfected with TLR4
(Cowland et al, 2003). In accordance, several TLRs,
including TLR4 and TLR2, are constitutively ex-
pressed in the CP and in cells lining the blood
vessels (Laflamme et al, 2003).
Irrespective of the molecular pathway that triggers
their expression, proteins secreted by the CP toward
the CSF may participate in the host’s defense against
CSF bacterial infections. Interestingly, in the pre-
sence of IFN-g, the supernatant of porcine CP
epithelial cells displayed a bacteriostatic effect
against Streptococcus suis. This was at least par-
tially attributed to the induction of indoleamine 2,3-
dioxygenase activity and the resulting depletion of
L-tryptophan (Adam et al, 2004). Given the data we
now present, it is also possible that the secretion of
LCN2 into the media also contributes to this
bacteriostatic effect. Recent studies clearly show
that LCN2-null mice exhibit increased susceptibility
to infection by bacteria that depend on entherocalin-
like siderophore-dependent iron uptake (Berger et
al, 2006; Flo et al, 2004). It will be interesting to
study the brain response to infection in these mice.
In summary, we describe here a novel acute-phase
response protein produced at the barriers between
the blood and the brain. By increasing the expres-
sion and secretion of LCN2, these barriers contribute
to restrict access of bacteria into the brain. This
adds CP and endothelial cells of blood vessels as
sites in which LCN2 expression is induced by
inflammation, and further supports a role for the
blood–brain and blood–CSF barriers as part of the
innate immune response against central nervous
system infection.
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Abstract 
 
Iron is essential for normal mammalian cellular homeostasis but, in excess, promotes free radical 
formation and is associated with neurodegenerative disorders such as Alzheimer’s disease. Iron 
is also required for microbial growth and in case of infection the host activates several 
mechanisms to prevent iron availability for bacteria. We have recently shown that by synthesizing 
and secreting lipocalin 2 into the cerebrospinal fluid (CSF), the choroid plexus can contribute to 
the brain innate immune response. Here we show that other iron-related genes participate in 
brain iron homeostasis. As early as 3h after intraperitoneal administration of lipopolysaccharide 
(LPS), hepcidin (HAMP) mRNA levels are up-regulated in the choroid plexus, returning close to 
basal levels at 24h. HAMP has been described as a liver-derived hormone that regulates iron 
availability by decreasing ferroportin (FPN)-mediated iron exportation from the enterocyte into the 
bloodstream. The expression of genes encoding for other proteins, also involved in the regulation 
of iron metabolism including ceruloplasmin, transferrin receptor type 2 (TFR2), interleukin-6 (IL-
6) and transcription factors such as signal transducer and activator of transcription 3 (STAT3), 
are also up-regulated by the peripheral inflammatory stimulus. We propose that upon an acute 
peripheral inflammatory stimulus HAMP decreases FPN-iron delivery into the CSF and increases 
iron uptake from the CSF, therefore decreasing iron availability for bacterial growth and 
dissemination within the brain. 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Choroid plexus; inflammation; iron metabolism; lipopolysaccharide; hepcidin. 
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Introduction 
Iron is a required element for normal cellular homeostasis, participating in processes that range 
from cell proliferation, oxygen transport and energy metabolism (Aisen et al., 2001; Papanikolaou 
and Pantopoulos, 2005). While iron deficiency leads to conditions such as anemia, in excess and 
by promoting free radical formation and oxidative stress, it is deleterious for the organism. Iron 
homeostasis is, therefore, tightly regulated. Hepcidin (HAMP), a liver-derived peptide hormone, 
has been recently described as the main iron regulator, by modulating iron release from the 
intestine into the plasma (Nemeth and Ganz, 2006; Darshan and Anderson, 2007), the rate 
limiting process in iron homeostasis (De Domenico et al., 2007). Iron is taken up from the diet by 
enterocytes, and it is released into the bloodstream through the iron exporter ferroportin (FPN). In 
conditions of iron sufficiency, HAMP secreted by the liver into the bloodstream reaches the 
enterocyte and binds to FPN which is then internalized and degraded (Nemeth et al., 2004). As a 
consequence iron is kept within the cell which results in lower iron release into the circulation. It 
has been shown that increased HAMP levels result in anemia (Means, 2004; De Domenico et al., 
2007) while decreased levels are associated with iron-overload diseases (De Domenico et al., 
2007). Once in the blood iron is mostly bound to plasma proteins, particularly to transferrin (TF), 
and is delivered to cells through TF receptor (TFR)-mediated endocytosis (Moos and Morgan, 
2000; Ponka and Lok, 1999). Within the cells, iron can be stored bound to ferritin (Harrison and 
Arosio, 1996). Iron homeostasis is challenged in several conditions such as infection by most 
microorganisms. As any other cell, microorganisms need iron for survival and proliferation and, 
upon infection, the host promptly responds by increasing the levels of several iron-binding 
proteins. Among these, ferritin and ceruloplasmin are well known liver positive acute-phase 
proteins (Ceciliani et al., 2002). However, most organisms secrete siderophores, molecules with 
higher affinity for iron than the major plasma iron-carrier proteins (Miethke and Marahiel, 2007). 
In response, the host, mostly circulating neutrophils but also hepatocytes, secretes lipocalin 2 
(LCN2) (Borregaard et al., 2007; Jayaraman et al., 2005), a protein that has the ability to 
sequester iron-loaded siderophores (Flo et al., 2004). 
Several studies have addressed how the innate immune system influences iron metabolism, but 
few focused on the brain. Understanding brain iron metabolism might be of particular interest 
since in aging mammals iron accumulation is believed to contribute to neurodegeneration (Zecca 
et al., 2004). It has been proposed that iron uptake by the brain depends on TF-mediated 
endocytosis by endothelial cells of the blood-brain barrier (Moos and Morgan, 2000; Moos et al., 
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2006). Iron would then be likely released through FPN (Rouault and Cooperman, 2006) into the 
interstitial fluid of the brain parenchyma and then taken up by oligodendrocytes again through 
TFR mediated endocytosis. 
Despite the observation that TF (Dickson et al., 1985), TFR (Giometto et al., 1990) and FPN (Wu 
et al., 2004) are synthesized by the choroid plexus, little attention has been paid to these 
structure in iron access into the brain. Of relevance, it has been recently shown that LCN2 is 
quickly synthesized and secreted by the choroid plexus into the cerebrospinal fluid (CSF) upon an 
inflammatory stimulus induced in the periphery (Marques et al., 2008). This observation 
suggests that limiting iron availability to microorganisms is part of the strategy set by the choroid 
plexus to fight potential infections of the central nervous system. Taken together, these 
observations prompted us to further investigate the choroid plexus iron homeostasis upon an 
inflammatory stimulus induced in the periphery. The data suggest that the choroid plexus has, for 
the brain, a similar role in iron metabolism of that played by both the liver and intestine for the 
rest of the body. 
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Materials and Methods 
Animals and LPS injection 
All experiments were conducted using 8-9 week-old C57BL/6 male mice, and Wistar neonates 
(postnatal day 1 or 2) rats (Charles River, Barcelona, Spain), in accordance with the European 
Community Council Directive 86/09/EEC guidelines for the care and handling of laboratory 
animals. Animals were maintained under 12h light/dark cycles at 22-24ºC and 55% humidity, 
and fed with regular rodent’s chow and tap water ad libitum. In order to reduce the stress-
induced changes in the hypothalamus-pituitary axis associated with the injection, animals were 
handled for 1 week prior to the beginning of the experiment. Animals were given LPS 
(Escherichia coli, serotype O26:B6; Sigma, St. Louis, USA) (5μg/g body weight) intraperitoneally 
(i.p.); control animals were injected with vehicle (0.9% NaCl) alone. 
Mice were anesthetized with ketamine hydrochloride (150mg/Kg) plus medetomidine 
(0.3mg/Kg), transcardially perfused with cold saline and sacrificed 1, 3, 6, 12, 24 or 72h after 
LPS injection. For the mRNA studies, choroid plexus was rapidly removed under conventional 
light microscopy (SZX7, Olympus, Hamburg, Germany), frozen in dry ice and stored at -80ºC. At 
least 5 pools of choroid plexus (from 3 animals each) were prepared for each time point. Adult 
rats similarly treated and sacrificed 6h after the LPS injection. Blood was collected, centrifuged 
and serum kept at -80ºC until use in cell culture stimulation (see below). 
 
qRT-PCR gene expression measurements 
RNA preparation and PCR from mice choroid plexus 
Total RNA was isolated from choroid plexus using Trizol reagent (Invitrogen, Carlsbad, CA, USA). 
500 ng of total RNA were amplified using the Superscript RNA amplification system (Invitrogen) 
according to the manufacturer’s instructions. RNA was reverse transcribed using random primers 
of the Superscript First-strand Synthesis System for RT-PCR (Invitrogen). 
qRT-PCR analysis was used to measure the expression levels of ceruloplasmin (Cp), ferritin light 
chain 1, (Ftl1) ferroportin (Slc40a1), hepcidin (Hamp), interleukin-6 (Il-6), the signal transducer 
and activator of transcription 3 (Stat3), transferrin receptor type 2 (Tfr2) and transferrin receptor 
(Tfr1), mRNA transcript. The reference gene, hypoxanthine guanine phosphoribosyl transferase 
(Hprt), was used as internal standard for normalization (gene abbreviations and gene names are 
specified in accordance with the HUGO Gene Nomenclature Committee available at 
http://www.genenames.org), since we have previously shown that its expression is not 
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influenced by the experimental conditions (Marques et al., 2008). The oligonucleotide primers for 
the transcripts analyzed were designed using the Primer3 software on the basis of the GenBank 
sequences: NM_001042611; NM_010240.1; NM_016917; NM_032541; NM_031168.1; 
NM_011486.2; NM_015799.2; NM_011638; NM_013556. The real-time PCR reactions, using 
equal amounts of total RNA from each sample, were performed on a LightCycler instrument 
(Roche Diagnostics, Basel, Switzerland) using QuantiTect SYBR Green RT-PCR reagent kit 
(Qiagen, Hamburg, Germany). Product fluorescence was detected at the end of the elongation 
cycle. All melting curves exhibited a single sharp peak at a temperature characteristic of the 
primers used. 
RNA preparation and PCR from rat choroid plexus 
Total RNA was collected after 6h of stimulation, and extracted using a Micro Scale RNA Isolation 
Kit (Ambion, Austin, TX, USA). The oligonucleotide primers for the transcripts analyzed were 
designed using the Primer3 software on the basis of the GenBank sequences: NM_053469 for 
Hamp; NM_031512), interleukin-1β (Il-1β); NM_012589 for Il6 and NM_012583 for Hprt that 
was used as internal standard for normalization. qRT-PCR was performed as described above. 
 
Primary cultures of rat choroid plexus epithelial cells 
Epithelial cells from rat choroid plexus were prepared as described previously by Strazielle and 
Ghersi-Egea, (1999) with minor modifications. Briefly, neonates (postnatal day 3 or 4) were 
sacrificed and choroid plexuses were dissected under conventional light microscopy. The tissue 
was rinsed twice in phosphate buffered saline (PBS) (without Ca2+ and Mg2+) followed by a 25 min 
digestion with 0.1mg/ml pronase (Sigma) at 37ºC. Predigested tissue was recovered by 
sedimentation and briefly shaken in 0.025% of trypsin (Invitrogen) containing 12.5μg/ml DNAseI 
(Roche). The supernant was then withdrawn and kept on ice with 10% fetal bovine serum (FBS) 
(Invitrogen). This step was repeated 5 five times. Cells were pelleted by centrifugation and 
ressupended in culture media consisting of Ham’s F-12 and DMEM (1:1) (Invitrogen) 
supplemented with 10% FBS, 2mM glutamine (Invitrogen), 50μg/ml gentamycin (Sigma), 
5μg/ml insulin, 5μg/ml transferrin, 5ng/ml sodium selenite (ITS, Sigma), 10ng/ml epidermal 
growth factor (Sigma), 2μg/ml hydrocortisone (Sigma), 5ng/ml basic fibroblast growth factor 
(Invitrogen). For further enrichment, cells were incubated on platic dishes for 2h at 37ºC. A 
differential attachment on plastic dish occurred, and supernant containing mostly epithelial cells 
was collected and placed for seeding on laminin (Boehringer Ingelheim, GmbH, Germany) coated 
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transwells (Corning, Lowell, MA, USA). 
Experiments were performed after the formation of confluent cell monolayers, approximately after 
7 days in culture. Choroid plexuses epithelial cells were stimulated in the basolateral side with 
various stimuli: serum collected from LPS-treated rats 6h after the LPS administration; LPS 
(200ng/ml), IL-6 (2.8ng/ml) or IL-1β (0.5ng/ml), in choroid plexus epithelial cells medium. 
Total RNA from choroid plexuses epithelial cells cultures was obtained at 6h after stimulation, 
and extracted using a Micro Scale RNA Isolation Kit (Ambion, Austin, TX, USA). 
 
Statistical analysis 
Values are reported as mean±SE. Statistical significance was determined using the non 
parametric Mann-Whitney test, with differences considered significant at p<0.05. 
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Results 
The choroid plexus alters, in vivo, iron metabolism in response to the peripheral 
administration of LPS 
Hamp expression is rarely detectable in the basal conditions by qRT-PCR, but it is up-regulated 
from 1 to 12h after LPS injection, reaching the maximum expression at 3h (Figure 1a), and 
returning almost to control levels at 24h. We next studied the expression of genes encoding 
proteins known to modulate Hamp expression in the liver. Expression of Tfr2 is strongly up-
regulated during the first 24h after induction of the peripheral inflammatory response (Figure 1b). 
Of notice the up-regulation of Il-6 is very rapid and transient, peaking at 3h after LPS injection, 
and returning almost to basal levels at 6h (Figure 1c). Response to IL-6 is known to activate 
STAT3; the expression of Stat3 increases up to 3h, and returns to basal levels at 24h after LPS 
injection (Figure 1d). 
 
 
 
Figure 1. Hepcidin (Hamp) mRNA expression is strongly induced by peripheral LPS peaking at 3h and returning to basal levels after 
24h (a). The possible upstream regulators of Hamp gene are also induced in the choroid plexus after peripheral LPS: Transferrin 
receptor type 2 (Tfr2) (b) and interleukin-6 (Il-6) (c). The signal transducer and activator of transcription 3 (Stat3) is also up-regulated in 
the choroid plexus in response to LPS (d). 
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In order to better characterize the overall alterations in the choroid plexus iron metabolism, the 
genes encoding other key proteins in the process were studied. Among these, the expression of 
the gene encoding for ceruloplasmin is increased at 3h and remains up-regulated until 24h after 
LPS injection (Figure 2a); while that of genes encoding for TFR1, FTL1, and FPN are not clearly 
modified in response to the inflammatory stimulus (Figure 2b, c and d).  
 
 
Figure 2. Expression levels of iron related protein in the choroid plexus after i.p. injection of LPS. Ceruloplasmin (Cp) mRNA expression is 
increased in response to LPS (a). No alterations were observed in the expression levels of transferrin receptor type 1 (Tfr1) (b), ferritin (Ftl1) (c) 
and ferroportin (Fpn) (d). 
 
Triggering effectors of the choroid plexus response 
The choroid plexus extracted for the in vivo analysis is composed not only by the choroid plexus 
epithelial cells, but also by cells that constitute the choroid plexus stroma, including essentially 
endothelial cells of the blood vessels but also eventually cells of the immune system like 
macrophages and dendritic cells. Thus, changes in the choroid plexus mRNA composition might 
result from altered gene expression of the choroid plexus epithelial cells and/or of stroma cells. 
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Therefore, and as an attempt to specifically identify the contribution of the choroid plexus 
epithelial cells to the choroid plexus response to peripheral inflammation, we used in vitro 
cultures of rat newborn choroid plexus epithelial cells. When exposed to serum collected from 
rats 6h after LPS administration, the epithelial cells response is similar to that observed in vivo. 
There is up-regulation of Hamp gene (Figure 3a) and also up-regulation of IL-6 and IL-1β (Figure 
3b and c, respectively). 
 
 
Figure 3. Serum collected from rats 6h after LPS injection is able to induce the expression of hepcidin (Hamp) (a), IL-6 (b) and IL-1β (c). 
 
It is acknowledged that the choroid plexus expresses receptors not just for LPS (the TLR4) but 
also for several immune molecules whose expression increases in the blood during inflammation. 
Thus, the altered gene expression associated with iron metabolism might result from a response 
to LPS alone and/or to immune modulators present in the blood. 
In another set of experiments, cells were exposed to various individual stimuli. As an attempt to 
discriminate among the various blood-born constituents which one(s) modulate iron metabolism 
in the choroid plexus. Preliminary data show that LPS or IL-6 alone do not seem able to induce 
alterations in the Hamp expression levels (Figure 4).  
 
 
Figure 4. LPS or IL-6 alone do not seem able to influence the expression of hepcidin (Hamp) in rat primary choroid plexus epithelial cell culture. 
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Discussion 
This study shows that the choroid plexus contributes to the brain iron metabolism reaction in 
response to peripheral inflammation. This regulation seems to be quick and transient, and 
highlights the choroid plexus as a prompt conveyor of signals from the periphery into the brain. 
Of notice, it shows that the gene encoding HAMP, rarely detected in basal conditions, is strongly 
up-regulated soon after LPS administration. HAMP is recognised as an endocrine hormone 
secreted by the liver and that, in the intestine, inhibits FPN-mediated iron release into the 
bloodstream, therefore reducing iron absorption. We suggest that HAMP in the choroid plexus 
may have an autocrine mode of action, similarly reducing FPN-mediated iron exportation into the 
CSF. On the other hand, by secreting TF and ceruloplasmin into the CSF, the choroid plexus 
might facilitate iron uptake by cells in contact with the CSF. In this way, HAMP in the choroid 
plexus could participate in the regulation of brain iron “absorption”. Iron entry into the brain has 
been characterized mainly through the endothelial cells that constitute the blood-brain barrier. 
Iron is believed to be taken up through TFR-mediated endocytosis (Moos and Morgan, 2000). 
Release of iron into the brain parenchyma is suggested to occur also through FPN, and less is 
known about iron access and distribution within the brain. The presence of TFR in neurons 
(Moos, 1995) and glia cells (Orita et al., 1990; Kaur and Ling, 1995) suggests that the process 
of iron uptake by cells is quite uniform. The data now presented provides evidence that, at least, 
in conditions of acute peripheral inflammation, the choroid plexus contributes to brain iron 
content. The quick regulation of iron metabolism in the choroid plexus might be particularly 
relevant in preventing dissemination of bacteria that reach the CSF and eventually the brain 
parenchyma. We have previously shown that LCN2, a sequester for bacterial iron-loaded 
siderophores is up-regulated in the choroid plexus, CSF and endothelial cells of the blood-brain 
barrier (Marques et al., 2008) after peripheral administration of LPS. Studies in Lcn2-null mice 
have shown increased rate of mortality and bacterial load in several organs (Flo et al., 2004). It 
would be interesting to investigate whether the same holds true for bacteria that normally infect 
the brain. The data of the present study extends further our knowledge on how the choroid plexus 
contributes to deplete circulating iron, which may prevent bacteria proliferation in the CSF and, 
consequently, dissemination within the brain.  
The trigger of the choroid plexus response to peripheral inflammation remains to be clarified. LPS 
is known to induce an acute-phase response in the liver and in other organs (Kramer et al., 
2008), and these react by secreting proteins such as interleukins. Among these, IL-6 has been 
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shown, in the liver, to regulate Hamp expression, upon interaction with the cognate cellular 
receptor, and through the STAT3 signalling transduction pathway (Kemna et al., 2005; Nemeth 
et al., 2004; Nemeth et al., 2003). However, the exact mechanism by which the body senses the 
iron status and regulates Hamp expression is not completely understood. The discovery of 
different forms of hereditary hemochromatosis (disorders of iron overload) caused by mutations 
in genes involved in iron homeostasis suggests some possible answers for this question. Patients 
with mutations in hemacromatosis (Hfe), Tfr2, hemojuvelin (Hjv) or Hamp genes, all show iron 
deposition that is similar and consistent with elevated iron absorption. HFE and TFR2 are two 
upstream regulators of Hamp expression. In the present study we did not find alteration in the 
expression levels of Hfe, but a strong increase in the Tfr2 levels were detected in the choroid 
plexus after LPS stimulation. The mechanism by which TFR2 regulates HAMP is not clear but the 
level of differic TF has emerged as a potential regulator (Frazer and Anderson, 2003; Wilkins et 
al., 2006). Tfr2 encodes a protein that shares 45% of identity with TFR1, but the expression is 
more restricted to the liver, spleen, brain and heart (Kawabata et al., 1999) and, as we now 
show, also the choroid plexus. The mechanism through which TFR2 regulates Hamp expression 
is unknown, but Hamp expression is down-regulated in Tfr2-mutant mice (Kawabata et al., 
2005). The affinity of TFR2 for TF is about 25 times smaller than that of TFR1 (West et al., 
2000), and although the transferrin is described as a negative acute-phase protein it is possible 
that iron saturation of the circulating serum TF in response to peripheral inflammation stimulates 
TFR2 occupancy and downstream activated pathways. We used in vitro cultures of rat choroid 
plexus epithelial cells as an attempt to discriminate among the potential modulators of the 
choroid plexus response to inflammation, with respect to iron homeostasis. The data clearly 
shows that LPS alone is able to induce the expression of Il6, Il-1β and Lcn2 (data not shown) but 
not several other genes implicated in iron metabolism. Preliminary results suggest that IL6, 
alone, is not able to induce the expression of any of the genes, including Hamp. It is therefore 
possible that the regulation of Hamp is mediated by TFR2 given the increase in blood of the basal 
TF as holo-TF. We are currently investigating this possibility. 
Irrespectively from the precise mechanisms, the overall response of the choroid plexus to 
peripheral inflammation includes changes in iron homeostasis. These modifications seem 
concordant with a reduction in iron availability in the CSF, as depicted in Figure 5, and 
consequently, as an important intervenient in the all innate immune response. Up-regulation of 
Hamp by the inflammatory stimulus may decrease FPN-mediated iron release into the CSF. In 
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addition, increased secretion of ceruloplasmin may facilitate iron binding to TF and internalization 
by the cells of the brain parenchyma. Finally, and in the case bacteria invade the CSF, lipocalin 2 
is promptly ready to sequester bacteria siderophores. Therefore, all together the response seems 
to restrict iron availability for bacteria. The precise modulator of such regulation remains however 
to be clarified. 
The ability of the choroid plexus to regulate iron metabolism in conditions of peripheral 
inflammation might impact on diseases such as Alzheimer and multiple sclerosis. The 
observations that an inflammatory component may underlie such diseases, that iron accumulates 
with aging, and that, ceruloplasmin-deficient mice exhibit increased iron accumulation and 
demyelination when exposed to LPS (Glezer et al., 2007), warrant that additional studies on 
choroid plexus iron metabolism in neurological diseases are necessary.  
 
Figure 5. Iron metabolism in the choroid plexus after LPS injection. 
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Abstract 
The choroid plexus (CP) is responsible for the production of cerebrospinal fluid (CSF) and is part 
of the blood-brain barriers. In addition, it has receptors and transporters for molecules such as 
neurotransmitters, immunomodulators, carrier proteins and nutrients, in both the apical and 
basolateral membranes. Therefore, it is ideally positioned to transmit signals from and into the 
brain. As part of the brain-barrier system, changes in the expression of CP proteins will ultimately 
influence the composition of the CSF and the information conveyed into the brain. Using 
microarray analysis the present study shows a specific acute-phase response of the mouse CP 
transcriptome after an inflammatory stimulus induced in the periphery by lipopolysaccharide 
(LPS). Remarkably, the response seems specific to a restricted number of genes; from a total of 
24,000 analysed genes, 252 were found up-regulated and 173 down-regulated, during the time 
course of the experiment. When clustered into families, the genes up-regulated are mostly 
implicated in immune-mediated cascades and in extracellular matrix remodelling, while those 
down-regulated encode for proteins involved in the maintenance of the CP barrier function. Of 
relevance, the transcriptome profile returns almost completely to basal levels 72h upon the 
inflammatory stimulus is triggered. It is therefore clear that the CP quickly and actively responds 
to peripheral inflammation and that the balance of such response should be considered in the 
final homeostasis of the brain in health and disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Choroid plexus; inflammation; lipopolysaccharide; pathway. 
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Introduction 
The precise mechanisms through which peripheral inflammatory stimuli trigger brain inflammation 
are poorly understood. Interest on the subject is increasing given the suggestion that an inflammatory 
state of the central nervous system (CNS) is implicated in neurodegenerative diseases such as 
parkinson´s (PD) and Alzheimer’s diseases (AD) and that is well recognized in multiple sclerosis (MS). 
While several studies have addressed the communication between the periphery and the CNS by 
looking at the blood-brain barrier (BBB), less have specifically addressed the participation of the blood 
choroid plexus (CP)-cerebrospinal fluid barrier (BCSFB). The CP, located within the brain ventricles, is 
composed by a vascularized stroma surrounded by a tight line of epithelial cells that control the 
cellular and molecular traffic between the blood and the cerebrospinal fluid (CSF) (Redzic and Segal, 
2004). Its better known function is the production of at least 2/3 of the CSF (Speake et al., 2001). 
The CP is therefore, ideally located to transmit signals into and out of the brain (Emerich et al., 2005). 
Following systemic administration of lipopolysaccharide (LPS), there is a rapid and transient CP 
induction of immune mediators such as interleukin IL-1β and TNF (Konsman et al., 2004; Marques et 
al., 2007; Nadeau and Rivest, 1999; Quan et al., 1998; Quan et al., 1999,), enzymes such as 
prostaglandin D2 synthase and bacteriostatic proteins such as lipocalin 2 (LCN2) (Marques et al., 2007; 
Marques et al., 2008). Accessory molecules important for leukocyte adhesion such as selectin, 
lymphocyte (L-selectin), intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 
1 (VCAM-1) are expressed in basal conditions at low levels but are up-regulated on CP epithelial cells 
during inflammation (Endo et al., 1998; Engelhardt et al., 2001; Wolburg et al., 1999), eventually 
facilitating access of immune cells into the brain. Of notice, it has been recently suggested in the 
experimental allergic encephalomyelitis model of MS that the CP may be the primary route of immune 
cells entry into the CSF (Brown and Sawchenko, 2007). Similarly, the CP may facilitate bacteria entry, as 
indicated in a mouse model of infection with Streptococcus suis (Dominguez-Punaro et al., 2007). The 
CP activation initiates a process that ultimately spreads throughout the brain suggesting that the CP 
transmits information between the immune system and the brain. The studies published so far on the 
CP mostly focus on single proteins or group of proteins. The full elucidation on how the CP stroma and 
epithelial cells respond to inflammatory stimulus and contribute to the brain innate and adaptative 
immune responses is far from understood. In the present study we evaluate the kinetic overall response 
of the CP to an acute inflammatory stimulus induced by the peripheral administration of LPS. We show 
that the CP displays a rapid transient acute-phase response to LPS. A model of signalling in the CP is 
proposed, and the major pathways influenced by the acute peripheral stimulus are highlighted. 
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Experimental procedures 
Animals and LPS injection 
All experiments were conducted using 8-9 weeks old C57BL/6 male mice (Charles River, 
Barcelona, Spain), in accordance with the European Community Council Directive 
86/09/EEC guidelines for the care and handling of laboratory animals. Animals were 
maintained under 12h light/dark cycle at 22.5ºC and 55% humidity and fed with regular 
rodent’s chow and tap water ad libitum. In order to reduce the stress-induced changes in 
the hypothalamus-pituitary axis, animals were handled for 1 week prior to the beginning of 
the experiment. Animals were injected intraperitoneally (i.p.) with LPS (5μg/g of body 
weight; Escherichia coli, serotype O26:B6; Sigma, St. Louis, USA) or vehicle alone (0,9% 
NaCl). Animals were anesthetized with ketamine hydrochloride (150mg/Kg) plus 
medetomidine (0.3mg/Kg), transcardially perfused with cold saline and sacrificed 1, 3, 6, 
12, 24 or 72 hours after LPS injection. For mRNA studies, the CP was rapidly removed, 
stored in RNA later (Ambion, Austin, TX, USA) and kept at -80ºC. CP isolation was made 
under conventional light microscopy (SZX7, Olympus, Hamburg, Germany). At least 3 pools 
of CP (from 3 animals each) were prepared for each time point. This experiment was 
performed twice: CP samples from one experiment were used for microarray analysis; CPs 
collected in independent experiment were used to confirm the results, by quantitative RT-
PCR (qRT-PCR), obtained in the array study. In this second experiment 5 pools of CP were 
prepared. 
 
Microarray experimental design and data analysis 
Total RNA was isolated with Trizol (Invitrogen, Carlsbad, CA, USA) following the 
manufacturer’s instructions. After quality assessment using the Agilent Bioanalyzer (Santa 
Clara, CA, USA), 100ng of total RNA from 3 pooled controls and 2 pooled samples of each 
time point were amplified and labelled with Illumina TotalPrep RNA Amplification Kit. The 
labelled cRNA was then hybridized using the recommended protocol in a total of two Illumina 
Whole-genome Mouseref-8 expression Beadchips (San Diego, CA, USA). This mouse 
beadchip contains eight arrays, each comprising a total of 24,000 well-annotated RefSeq 
transcripts. 
After scanning, raw data from BeadStudio software (San Diego, CA, USA) was read into 
R/Bioconductor and normalized using quantile normalization. A linear model was applied to the 
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normalized data using Limma package in R/Bioconductor (Gentleman et al., 2004). A contrast 
analysis was applied and differentially expressed genes were selected using a Bayesian approach 
with a false discovery rate of 0.5%.  
The differentially expressed genes were categorized using Gene Ontology from Biomart 
(http://www.biomart.org/) or Ingenuity tools (Redwood City, CA, USA). Enrichment analysis was 
performed using the DAVID (http://david.niaid.nih.gov/david/ease.htm) and the Ingenuity 
softwares. 
 
Gene expression measurements by qRT-PCR 
500ng of total RNA isolated as described above were amplified using a SuperScript RNA 
Amplification System (Invitrogen) according to the manufacturer’s instructions. After 
amplification, RNA was reverse transcribed into first strand cDNA using random hexamers of the 
Superscript First-strand Synthesis System for RT-PCR (Invitrogen) accordingly to the 
manufacturer’s instructions.  
qRT-PCR analysis was used to measure the expression levels of selected mRNA transcripts. 
Primers were designed using the Primer3 software (Rozen and Skaletsky, 2000) on the basis of 
the respective GenBank sequences. The expression level of the reference gene hypoxanthine 
guanine phosphoribosyl transferase (Hprt) (accession number from GenBank: NM_013556) was 
used as internal standard for normalization, since we have first confirmed that its expression is 
not influenced by the experimental conditions. 
All the other accession numbers are available upon request. Reactions using equal amounts of 
total RNA from each sample were carried out on a LightCycler instrument (Roche Diagnostics, 
Basel, Switzerland) with the QuantiTect SYBR Green RT-PCR reagent kit (Qiagen, Hamburg, 
Germany) according to the manufacturer’s instructions. Product fluorescence was detected at the 
end of the elongation cycle. All melting curves exhibited a single sharp peak at the expected 
temperature. 
 
Statistical analysis 
Values are reported as mean±SE. Statistical significance was determined using the non 
parametric Mann-Whitney test, with differences considered significant at p<0.05. 
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Results 
Reproducibility of the gene array data 
As described above, 2 pooled CP samples for each LPS time point were compared with 3 pooled 
CP samples from saline-injected animals. Data was analyzed in the Bioconductor. Quality control 
using inter-array Pearson correlation and clustering based on variance allowed us to ensure the 
reproducibility between the replicates. After data normalization, the differentially expressed genes 
were selected based on a false discovery rate (FDR) of 0.5%. We obtained a final list of 324 
differentially expressed genes considering all the time points.  
 
Gene expression kinetic profile of the choroid plexus after and inflammatory 
peripheral stimulus 
As shown in Figure 1, that depicts the number of genes up- and down-regulated throughout the 
experimental period, the CP displays an acute-phase response to LPS.  
 
 
 
Figure 1. Number of genes whose expression is found altered after a peripheral injection of LPS. The CP gene expression profile was analysed 
from mice 1, 3, 6, 12, 24 and 72 hours after LPS administration, and compared with that from saline-injected mice. In red are represented the 
up-regulated and in green the down-regulated genes. 
 
 
The CP response to the LPS stimulus peaks at 3-6h. Of notice, at 1h, only 50 and 26 genes are 
up-regulated and down-regulated, respectively, but 2h later (time point 3h) 197 and 127 genes 
are up- and down-regulated, respectively. The CP response starts to slow down at 6h after the 
LPS stimulation and returns to basal levels, for most of the genes, at 72h. Table 1 lists the genes 
for which the expression is most altered, for each time point after the LPS injection. 
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Identification of altered gene pathways 
Gene ontology and biological pathway analysis of differentially expressed genes was 
performed using the ingenuity software and the DAVID program. This analysis shows that the 
major altered biological pathways are related with innate immune recognition, as depicted in 
Table 2.  
 
Table 2. Clustering of the genes whose expression is altered in the choroid plexus upon peripheral LPS injection. 
 
 
 
Confirmation of array results by qRT-PCR on a set of relevant genes 
Within each pathway, and using RNA extracted from CP pools of an independent experiment, a 
number of genes were chosen to confirm the array data by qPCR: Lcn2, Il6, Stat3, Saa3, Cxcl1, 
Timp1, Tap2, Tlr2, Icam1, Cd14, Socs3, Stat1, Irf1 and Irf7 as up-regulated genes and Cldn5, 
Cldn11, Lama2 and Gjb6 as down-regulated genes (Figure. 2).  
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Figure 2. Gene expression analysis, by qRT-PCR, from CP of saline and LPS injected mice. Confirming the array results, we show that the 
expression of Saa3, Cxcl1, Irf7, Irf1, Stat1 and Socs3 (a-f) are up-regulated and that of Cldn5, Cldn11 and Gjb6 (g-i) are down-regulated. 
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Proteins involved in barrier function and in cell adhesion during the choroid plexus 
acute-phase response to inflammation 
Most of the genes whose expression is found altered are up-regulated, but those encoding 
proteins that are involved in the formation of the tight junctions are down-regulated after the LPS 
injection (Table 2). Among those down-modulated are claudin 3 (Cldn3), claudin 11 (Cldn11) and 
claudin 5 (Cldn5). Also down-regulated are proteins of the extracellular matrix that contribute to 
cell-to-cell interactions such as endothelial cell-specific molecule 1 (Esm1), integrin alpha 8 
(Itga8), nidogen 1 and 2 (Nid1/2), protocadherin 7 (Pcdh7), laminin alpha 2 (Lama2) and 
decorin (Dcn). 
On the contrary, the Icam1 and the mucosal vascular addressin cell adhesion molecule 1 
(Madcam1) are up-regulated after the LPS treatment. In addition, proteins involved in leukocyte 
transendothelial migration, such as selectin, platelet (P-selectin) (Selp) and selectin, endothelial 
cell (E-selectin) (Sele) are also up-regulated. Degradation of extracellular matrix is achieved 
through the actions of proteases and the role of matrix metalloproteinases (MMPs) has been 
extensively investigated in this context (Flannery, 2006). In this study we observe an up-
regulation of the genes encoding proteases such as collagenase 13 (Mmp13) and the 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 1, 4 and 7 (Adamts1, 
Adamts4 and Adam7) which may contribute to the leakage of the BCSFB. Of notice, the 
expression of the gene encoding the tissue inhibitors of metalloproteinase Timp-1 is also up-
regulated already at 3h after the injection, in what might be perceived as a response 
mechanism to avoid extracellular matrix degradation. Taken together these observations 
suggest that cell migration might be facilitated in transient conditions of a compromised 
BCSFB. 
 
Acute-phase proteins during the choroid plexus response to lipopolysaccharide 
One of the most investigated, but still not well understood, characteristics of the acute-phase 
response is the up-regulation, or down-regulation, of many plasma proteins, known as positive 
and negative acute-phase proteins, respectively. The altered concentration of these proteins 
results from changes in the synthetic and secretory liver machineries as an adaptation to the 
stimulus. Several well described liver acute-phase proteins (Ceciliani et al., 2002; Gabay and 
Kushner, 1999) are also up-regulated in the CP soon after the LPS injection. For instances, a 
peak in the expression of serum amyloid A 1 (Saa1) and serum amyloid A 3 (Saa3) in the CP is 
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observed at 3h and 12h, respectively, after LPS injection. The purpose of the acute-phase 
reaction in the periphery is to counteract the underlying challenge and to restore homeostasis. 
This result is accomplished by isolating and destroying the infective organisms, or removing the 
harmful molecules, and activating the repair process. Acute-phase reaction includes a wide range 
of neuroendocrine, hematopoietic, metabolic and hepatic changes (Ceciliani et al., 2002). The 
production of some of the peripheral acute-phase proteins by the CP could represent a 
mechanism of defence within the brain similar to that observed in the periphery. Among these is 
Lcn2 (Sunil et al., 2007), an iron sequestering protein relevant to fight bacterial infection (Flo et 
al., 2004), and previously shown to be induced in the CP by the LPS stimulus (Marques et al., 
2008). 
 
Signalling transduction pathways involved in the choroid plexus response to 
lipopolysaccharide 
We find no alterations in the expression of Toll-like receptor 4 gene (Tlr4), the best well known 
and recognized target for LPS, but rather an increase in that encoding TLR2 in accordance with 
previous findings by Laflamme et al., (2001). The expression of the gene encoding CD14, a 
down-stream modulator in the TLR4- and TLR2-mediated cascades is, however, increased. This 
may indicate that the TLR2- and TLR4-mediated signal transduction pathways are induced by 
LPS. 
The expression of genes belonging to various well described signalling transduction pathways 
[Janus kinase/signal transducer and activator of transcription (JAK-STAT), mitogen-activated 
protein kinase (MAPK), nuclear factor kappa B (Nf-Kβ) and interferon regulatory factors (IRFs)] 
are altered by the LPS stimulus. These include several of the intermediate modulators and 
transcription factors, such as the Nf-kβ, IRF 1, 2, 7 and 9 (Irf1, Irf2, Irf7, Irf9), activated protein-1 
(AP-1), Stat1 and Stat3, which are all up-regulated. Many of these genes have, as downstream 
targets, genes encoding cytokines such as Il-1β, Il6, and chemokines such as (C-C motif) ligand 3 
(Ccl3), chemokine (C-C motif) ligand 4 (Ccl4). Other known target genes are those encoding for 
ICAM1 and MMP13 which are also induced as mentioned before. 
Of notice, the CP is not only able to activate these pathways but also to synthesize molecules 
responsible for the induction of inhibitory mechanisms as is the case of the proteins that belong 
to the SOCS family. In our array the suppressor of cytokine signalling 2 (Socs2) and suppressor 
of cytokine signalling 3 (Socs3) appear up-regulated. 
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Discussion 
The present study reveals that the CP displays an acute-phase response to an inflammatory 
stimulus induced in the periphery. As part of the blood-brain barriers, and because it influences 
the composition of the CSF, changes in the CP gene expression profile might influence the brain 
response to inflammation. Of notice, the kinetic profile presented by the CP is similar to that of 
the liver ( Sunil et al., 2007;  Vemula et al., 2004), with respect not only to the onset but also to 
the time in which the expression profile returns to the basal state. In addition, the acute 
responses both in the liver and in the CP share common pathways such as the Nf-Kβ, JAK/STAT 
and MAPK pathways. On the other hand, the nature of the CP epithelium reveals particular 
genes, especially those related with the barrier function, that are specifically implicated in 
intercellular junctions, both the tight junctions and the adherens junction, and that are altered by 
the inflammatory stimulus. Previous studies have shown induction of cytokines (Marques et al., 
2007; Thibeault et al., 2001; Nadeau and Rivest, 1999; Brochu et al., 1999; Tonelli et al., 
2003), acute-phase proteins (Schreiber et al., 1989; Marques et al., 2008) and major 
constitutively expressed proteins (Marques et al., 2007; Dickson et al., 1985) in the CP in 
response to acute peripheral inflammation. However, with the present data, the recognition that 
the CP, as a whole, mounts a specific and transient acute phase response becomes evident. 
It is well known that many disorders change the functionality and integrity of the BBB. BBB 
breakdown or alterations in transport systems play an important role in the pathogenesis of many 
CNS diseases (HIV-1 encephalitis, AD, MS, PD, ischemia and tumors) (Persidsky et al., 2006; 
Avison et al., 2004). Although the response of endothelial cells of the blood vessels that form the 
BBB to an inflammatory stimulus is not completely known, it is reasonable to expect that the CP 
response shares many of the mechanisms already described for the BBB. Together with studies 
implying particular CP proteins in diseases such as AD (Carro et al., 2005; Sousa et al., 2007) 
the present study warrants the need for further addressing the CP transcriptome in neurological 
and psychiatric diseases. Pro-inflammatory substances produced by microglia and specific 
disease-associated proteins (β-amyloid in AD and reactive T cells in MS) often mediate BBB 
dysfunction. These pro-inflammatory substances include cytokines, chemokines, reactive oxygen 
species, glutamate, and MMPs that may alter the integrity of the tight junctions. As we now show 
here, the CP may well be, as well, the source of many of these deleterious substances. In fact the 
integrity of the BBB is compromised in diseases with an important inflammatory component, for 
which there is leukocytes entry into the brain (Wong et al., 2007; Archambault et al., 2005). A 
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number of studies support the idea that changes in BBB endothelial cell tight junctions and 
cytoskeletal organization facilitates leukocyte migration. Adhesion molecules, such as E-selectin, 
VCAM-1, and ICAM-1, were proposed as key molecules in the interaction with leukocytes and in 
inducing functional changes in the BBB endothelial cells (Engelhardt, 2006). The data we now 
present on the CP show decreased expression of tight junction proteins and increased expression 
of proteins that facilitate migration. This may underlie the preferential migration of T lymphocyte 
across the BCSFB observed in animal models of MS (Brown and Sawchenko, 2007) and 
supports a relevant role of the CP in cell entry into the CSF and ultimately into the brain 
parenchyma. 
Apart from the role of the CP as a potential site of cell entry into the brain, due to leakage of its 
barrier function, the CP is also an active site of protein synthesis. Several inflammatory markers 
have been described in the CSF of individuals with CNS diseases (Andreasen and Blennow, 
2005; Giovannoni, 2006). The precise origin of these molecules is still a matter of debate, but 
the CP could greatly contribute for their presence in the CSF. In disease, or in response to 
various stimuli, the nature of the proteins secreted by the CP may change, as has been already 
shown for various cytokines, carrier proteins and iron-related proteins (Marques et al., 2007, 
2008; Hughes et al., 2002; Thibeault et al., 2001). The inflammatory chemokines, CCL5, 
CXCL10 and CCL2, whose genes have expression altered in the CP after peripheral LPS 
injection, are increased in the CSF of MS subjects (Trebst and Ransohoff, 2001). CCL2 up-
regulation in the CP has been previously shown by in situ hybridization (Thibeault et al., 2001), 
and here in the CSF (data not shown) after a single systemic bolus of LPS. While these may 
originate in the BBB or in the brain parenchyma, as suggested, it is likely that the CP, at least in 
part, also contributes. In addition, secondary lymphoid chemokines such as CXCL12, CXCL13 
detected in the CSF of MS patients (Corcione et al., 2004) are equally up-regulated in the CP. 
Other proteins such as MMP-9 and TIMP-3 have been described in the CSF of patients with 
meningitis (Kolb et al., 1998). The origin of such proteins may also likely be the CP. It is 
interesting that the balance between matrix metalloproteinases and their tissue specific inhibitors 
is crucial for extracellular matrix degradation. It is still unclear whether, as a whole, the CP 
response to peripheral inflammation favours one or the other, since we also find Timp1 up-
regulated at the same time points in which MMPs are induced. Similarly, the balance between 
pro- and anti-inflammatory molecules and how this relates to the final message transmitted into 
the brain is far from being understood. The CP synthesises and secretes into the CSF both pro-
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inflammatory (IL-1β, IL-6 and TNF) and anti-inflammatory (TGF-β) cytokines (Chodobski and 
Szmydynger-Chodobska, 2001). Anti-inflammatory, neuroprotective and antioxidant proteins such 
as metallothioneins -I and –II are increased and suggested as protective in neurodegenerative 
diseases such MS (Penkowa et al., 2001 Espejo et al., 2005), and AD (Carrasco et al., 2006). 
Under basal conditions, Espejo et al., (2005) have described low expression of MT-I and -II in the 
ependyma, CP, and meninges; and their expression is increased in the recovery phase of MS 
models being therefore suggested as protective. Of interest, LPS has been shown to induce the 
expression of metallothioneins in whole brain extracts (Zheng et al., 1995); and the present data 
shows that the CP certainly contributes to such increase. 
Other recent observations add to the neuroprotective role of the CP, since in response to LPS the 
CP regulates iron metabolism by inducing a decrease in iron availability for microorganism 
proliferation within the CNS (Marques et al., 2008, Chapter 4). 
Irrespectively from the final balance, the present data give us insight on the signalling 
transduction pathways that ultimately result in the observed altered gene expression profile 
(Figure 4). In response to the peripheral administration of LPS, the serum concentration of 
several cytokines, such as IL1β and IL6 is increased (Ramadori and Christ, 1999). Since 
receptors for these cytokines have been described in the epithelial cells of the CP (Chodobski and 
Szmydynger-Chodobska, 2001), and also found in basal conditions in our array, both LPS- and 
cytokine-mediated signalling transduction pathways may be operating simultaneously in response 
to peripheral inflammation. They may in fact be more relevant than LPS for the final response 
since the transcriptome of CP cells cultured in vitro in the presence of LPS display a much 
reduced response with only a few proteins up-regulated (Thouvenot et al., 2006). 
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Figure. 4. Suggested pathway of the CP epithelial cells response to peripheral injected LPS. In green are the genes that are, in one or more time 
points, down-regulated, in red are the genes that appear up-regulated during one or more time points of the kinetic study.  
 
LPS is the natural ligand of TLR4, which is expressed in the CP and in the circuventricular 
organs within the brain (Laflamme and Rivest, 2001). While we find no effect of LPS on the 
levels of TLR4, the expression levels of the gene encoding CD14 are strongly induced, and 
increased levels of CD14 may well contribute to the activation of TLR4. Of notice, and similarly 
to what has been described previously (Laflamme et al., 2001), we observed an increase in the 
expression of TLR2. Identical observations were described in splenic macrophages (Matsuguchi 
et al., 2000). While LPS is not described as a ligand for TLR2, it is possible that molecules 
such as CD14, whose expression is quickly induced, contribute to its activation. In the TLR-
mediated signalling pathways, CD14 is known as a co-receptor for TLR2 and TLR4 (Rallabhandi 
et al., 2006; Remer et al., 2006; Viriyakosol et al., 2000) but it may act as a direct agonist for 
TLR2 when other ligands are absent (Bsibsi et al., 2007). Alternatively, signalling through TLR4 
may ultimately lead to TLR2 activation (Matsuguchi et al., 2000). Activation of Toll-like 
receptors and of receptors for IL-1β, IL-6 and TNF induces several transcription factors, 
including interferon regulatory factor 3 (IRF3), activator protein -1 (AP-1) and the NF-kβ 
(Colonna, 2007; Honda and Taniguchi, 2006a; Honda and Taniguchi, 2006b). We show here 
that several genes encoding proteins belonging to the NF-Kβ, the MAPK, STAT-JAK and IRFs 
 89 
signalling pathways are induced during the CP acute-phase response (Table 2) and these are 
described to contribute in numerous ways to the development and regulation of innate and 
adaptative immune responses (Ihle, 2001; Rawlings et al., 2004; Wesoly et al., 2007; Decker 
et al., 2002). It is therefore noticeable that the CP, as has also been demonstrated for the BBB 
endothelium (Laflamme et al., 1999; Laflamme and Rivest, 1999), responds to peripheral LPS 
through activation of all these pathways. This activation may also result in posttranslational 
modifications of transcription factors such as the phosphorylation of STATs, which should next 
be investigated.  
Termination of the CP acute-phase response is observed at 72h after stimulation. This might be 
the consequence of the negative feedback inhibition of STAT signalling by SOCS/CIS (Cooney, 
2002; Naka et al., 2005; Nicola and Greenhalgh, 2000), whose expression we also found 
increased after LPS administration; this seems to occur as well in the BBB (Lebel et al., 2000).  
 
In summary, the present study shows that the CP displays an acute-phase response similar to 
the one observed in the liver. This ultimately results in the release of immune modulators, both 
pro- and anti-inflammatory, into the CSF; and in the loosening of the barrier properties of the CP. 
The final balance and consequence for an immune response within the brain parenchyma 
remains to be elucidated, but it may contribute to the inflammatory component underlying 
diseases such as AD and MS. Highlighting the CP as a relevant mediator in the crosstalk between 
the immune and the CNS, the present study strongly suggests that the CP should be thoroughly 
considered in the final brain homeostasis in health and disease. 
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Abstract 
It is recognized that a chronic systemic inflammation might trigger alterations in the central 
nervous system (CNS). Several illnesses of the CNS, including multiple sclerosis and Alzheimer’s 
disease have an underlying chronic inflammatory component. Whether and how peripheral 
inflammation contributes in triggering the brain response in the course of such illnesses is far 
from understood. As part of the barriers that separate the blood from the brain, the choroid 
plexus (CP) may convey immune signaling into the brain; particularly given its function as the 
major producer of the cerebrospinal fluid (CSF). The composition of the CSF is altered in various 
CNS diseases, for which the CP secretome certainly contributes. In the present study we 
investigated the CP gene expression profile in response to a chronic inflammatory stimulus, 
induced by the intraperitoneal administration of lipopolysaccharide every two weeks for a period 
of three months. The data shows that the CP displays a sustained response to the chronic 
inflammatory stimulus by altering the expression of several genes. Major altered pathways 
include those facilitating cells entry into the CSF, and others that participate in the innate 
immune response to infection by microorganisms. Whether the final balance of the CP response 
is protective or deleterious for the CNS remains to be clarified and should be considered in the 
context of the brain response to inflammation. 
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Introduction 
Inflammation is implicated in the appearance and in the progression of central nervous system 
(CNS) diseases such as multiple sclerosis (MS) and Alzheimer’s diseases (AD), although the 
mechanisms are poorly understood (Cunningham et al., 2005; Chen et al., 2008; Tan et al., 
2007; Qin et al., 2007). It is well accepted that the inflammation observed in some of these 
diseases may originate in the periphery (Bar-Or, 2008; O'Connor et al., 2008; Dunn, 2006), 
particularly when the inflammatory stimulus persists as is the case in chronic inflammation. 
Persistent or chronic inflammatory signals can result in the inappropriate recruitment of 
leukocytes and cause localized or disseminated tissue dysfunction and damage, ultimately 
resulting in brain pathology. 
The natural mediators of the communication between the periphery and the brain are the blood-
brain barriers, constituted by the endothelial cells of the blood capillaries (blood-brain barrier-
BBB) and by the epithelial cells of the choroid plexus (CP) that separate the blood from the 
cerebrospinal fluid (BCSFB). Most studies published to date address the BBB interactions in 
response to acute peripheral stimulus or in the context of CNS diseases (Banks, 2005; 
Engelhardt and Ransohoff, 2005; Engelhardt, 2006). However, several reports have identified 
genes whose expression is altered in the CP mostly by acute peripheral inflammation. Among 
these are proinflammatory cytokines such as tumor necrosis factor (TNF) (Nadeau and Rivest, 
1999; Brochu et al., 1999), interleukin-1β (IL-1β) (Tonelli et al., 2003) and interleukin-6 (IL-6) 
(Brochu et al., 1999); adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1), 
intercellular adhesion molecule 1  (ICAM-1), P- and E-selectins (Carrithers et al., 2000; Lopez et 
al., 1999). We have previously shown that the CP mounts an acute-phase response to a single 
bolus injection of lipopolysaccharide (LPS), triggering molecular pathways that are both 
neuroprotective and deleterious for the brain. Deleterious because it results in the secretion of 
proinflammatory cytokines into the CSF, in the decreased expression of proteins that form the 
epithelial cells tight junctions and in the increased expression of proteins that may facilitate 
leukocyte trafficking into the brain. Protective since it modulates iron metabolism in a way that 
may prevent microorganism entry into and dissemination within the brain. While these 
observations relate to the CP response to acute inflammatory stimulus, they also suggest that the 
CP may as well be equipped to maintain a sustained response to peripheral inflammation. 
Of notice, several scattered but relevant reports have shown that the CP may contribute to the 
aetiology of CNS diseases in which persistent rather than acute inflammation is more likely to 
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persist. In MS the CP has been proposed as the main route of leukocyte entry into the brain 
(Brown and Sawchenko, 2007). In AD, the CP has been proposed to participate in amyloid β 
peptide clearance out of the brain, through CSF carrier proteins (e.g. transthyretin and 
apolipoprotein J) (Golabek et al., 1995) that bind to receptors (e.g. megalin) (Hammad et al., 
1997; Sagare et al., 2007; Zlokovic et al., 1996; Carro et al., 2005) in the apical membrane of 
the CP epithelial cells. Again, the CP seems able to mediate both neuro-deleterious and neuro-
protective pathways. 
These observations prompted us to investigate further how the CP transmits immune signals into 
the brain, in response to peripheral chronic inflammation. 
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Materials and Methods 
Animals and LPS injection 
All experiments were conducted using 8-9 week-old C57BL/6 male mice (Charles River, 
Barcelona, Spain), in accordance with the European Community Council Directive 86/09/EEC 
guidelines for the care and handling of laboratory animals. Animals were maintained in 12 h 
light/dark cycles at 22-24ºC and 55% humidity and fed with regular rodent’s chow and tap water 
ad libitum. In order to reduce stress-induced changes in the hypothalamus-pituitary axis 
associated with the injection, animals were handled for 1 week prior to the beginning of the 
experiment. Animals were given LPS (Escherichia coli, serotype O26:B6; Sigma, St. Louis, USA) 
(5μg/g body weight) intraperitoneally (i.p.); control animals were injected with vehicle (0.9% 
NaCl) alone. 
Mice received i.p. LPS or vehicle injections once every 2 weeks for 3 months. 
Animals were sacrificed 3 or 15 days after the last LPS or saline injection, under anesthesia with 
ketamine hydrochloride (150mg/Kg) plus medetomidine (0.3mg/Kg), and transcardially perfused 
with cold saline. For the mRNA studies, CP isolation was made under conventional light 
microscopy (SZX7, Olympus, Hamburg, Germany) and tissue was rapidly removed, frozen in dry 
ice and stored at -80ºC. At least 3 pools of CP (from 3 animals each) were prepared for each 
time point and for each treatment. 
 
Microarray experimental design and data analysis 
Total RNA was isolated using Trizol reagent (Invitrogen, Calrsbad, CA, USA). Total RNA quality 
was assessed using the Agilent Bioanalyzer (Santa Clara, CA, USA). After quality assessment, 
100ng of total RNA from 3 pooled controls and 3 pooled samples for each time point were 
amplified and labelled with Illumina TotalPrep RNA Amplification Kit according to manufacturer 
instructions. The labelled cRNA was then hybridized using Illumina recommended protocol in a 
total of two Illumina Whole-genome Mouseref-8 expression Beadchips (San Diego, CA, USA). This 
mouse beadchip contains eight arrays, each comprising a total of 24,000 well-annotated RefSeq 
transcripts. 
After scanning, raw data from BeadStudio software (San Diego, CA, USA) was read into 
R/Bioconductor and normalized using quantile normalization. A linear model was applied to the 
normalized data using Limma package in R/Bioconductor (Gentleman et al., 2004). A contrast 
analysis was applied and differentially expressed genes were selected using a Bayesian approach 
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with a false discovery rate (FDR) of 5%. 
Three pools of LPS injected animals were analysed and compared with control animals. Data was 
analyzed in the Bioconductor. Quality control using inter-array Pearson correlation and clustering 
based on variance allowed us to ensure that there was reproducibility between the replicates 
(data not shown). After data normalization, the differentially expressed genes were selected 
based on FDR of 5%. 
The differentially expressed genes were categorized using Gene Ontology from Biomart 
(http://www.biomart.org/) or Ingenuity tools (Redwood City, CA, USA). Enrichment analysis was 
performed using the DAVID (http://david.niaid.nih.gov/david/ease.htm) and the Ingenuity 
softwares. 
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Results: 
Chronic peripheral inflammation induces a manifest alteration in the choroid plexus 
gene expression profile 
Mice were administered with LPS once every 2 weeks for 3 months and were sacrificed 3 and 15 
days after the last LPS injection. These time-points were chosen since we have previously shown 
(chapter 5) that 3 days after a single LPS injection almost no genes had an altered expression. 
Moreover, as LPS was administered every 15 days, the analysis at 2 weeks after the last injection 
would allow us to evaluate if the gene profile was continuously altered during chronic inflammation.  
Figure 1 shows that 3 days after the last LPS injection more than 500 genes (536 genes) have 
an altered expression when compared to saline injected animals. Since at the same time-point, 
after a single LPS injection, only 46 genes were found to have an altered expression, the 
response we now find might be attributed to the chronicity of the stimuli. A response of the CP to 
the continuous peripheral stimuli is still present 15 days after the last injection; suggesting that 
contrary to what is observed upon a single acute stimulus, repetitive LPS injections do not allow 
the CP gene expression profile to recover as quickly. 
 
 
Figure 1. Chronic inflammation induces an altered CP gene expression profile. Number of genes up-regulated (red) and down-regulated (green) 
in the CP 3 and 15 days after the last injection of the chronic peripheral treatment with LPS. All genes with a variation in expression of at least 
20% (p<0,05) were considered. 
 
Despite the number of genes whose expression is found statistically altered, not many display a 
sustained fold change higher than 50% (Figure 2). In fact, as can be observed in Figure 2a, 3 
days after the last LPS injection, from the 369 genes whose expression is up-regulated, only for 
25 the fold change is ≥2,0. In addition, from the 167 genes whose expression is down-
modulated, none shows a strong down-modulation and only 7 display a decrease ≥1,7 (Figure 
2a). The fold changes are even smaller (but still statistically significant) at 15 days after the last 
LPS injection (Figure 2b); only 2 genes present a fold increase ≥2,0. 
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Figure 2. The fold change induced in most genes by the chronic stimulus is below 50%, both 3 days (a) and 15 days (b) after the last 
lipopolysaccharide administration. 
 
Table 1 lists the 25 genes that showed at least a 2-fold up-regulation at 3 days. For the genes 
whose expression was down-regulated at 3 days, or up- and down-regulated at 15 days, we focused 
our attention on those whose expression showed at least a 40% change (Tables 2, 3 and 4). 
 
Table 1. Genes whose expression is induced more that 2-fold 3 days after the last LPS injection 
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Table 2. Genes whose expression is at least 40% down-regulated 3 days after the last LPS injection. 
 
 
 
Table 3. Genes whose expression is at least 40% up-regulated 15 days after the last LPS injection. 
 
 
 
Table 4. Genes whose expression is at least 40% down-regulated 15 days after the last LPS injection. 
 
 
 
To understand the genes that are continuously altered during a chronic process of peripheral 
inflammation we looked for the genes whose expression was altered, at least 40%, both at 3 and 
at 15 days after the last LPS stimulus. Only 7 fulfilled such criteria (Table 5). No down-regulated 
genes are common at 3 and 15 days. 
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Table 5. Genes whose expression is at least 40% altered both at 3 and at 15 days after the last LPS injection. 
 
 
We next analysed, using the Ingenuity software, the pathways to which the genes altered at 3 and 
15 days after the chronic LPS treatment belonged. From Figure 3 it is clear that 15 days after the 
last LPS injection only a few genes are still altered within each biological pathway.  
 
 
 
Figure 3. Annotation-based functional analysis of gene expression changes after sustained injection of lipopolysaccharide – comparative analysis 
between the two time points analysed. 
 
 
When compared to the acute response presented in chapter 5, it should be notice that: only one 
gene (rather then 13) of the acute phase response signalling, one gene (rather then 6) of the 
chemokine signalling, 2 genes of the complement system (rather then 6) and 3 (rather then 4) 
from the antigen presentation pathway was found altered 3 days after an acute stimuli, showing 
that these alterations are certainly associated with the chronicity of the model used here. 
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Discussion 
A repetitive inflammatory peripheral stimulus induces an altered gene expression pattern that is 
still present 3 and even 15 days after the last LPS injection. We have previously shown that 3 
days after an acute LPS injection only 46 genes were altered and with a tendency to 
normalization. Of these, only 12 coincide with genes we now found altered at 3 days after the last 
injection of the continuous LPS treatment. Therefore, we can conclude that most of the 
alterations we now observe result from the chronicity of the inflammatory stimuli. However, it 
seems that the repeated injection of LPS induces in the CP the sustained transcription of specific 
molecules already found altered upon a single LPS injection. Namely, molecules known to kill or 
neutralize microorganisms such as the enzyme lysozyme (LYZS) or the bacteria siderophore-iron 
sequester protein, lipocalin 2 (LCN2) and elements of the complement (e.g. complement 
component 2, component 3, component 1 q subcomponent alpha polypeptide). 
When the overall CP response is evaluated in terms of the major biological pathways, 3 days after 
the last LPS administration, the CP response is mainly characterized by the increased synthesis 
of chemokines, complement system activation, activation of the leukocyte extravasation signalling 
and activation of the NK and B cell signalling. Of notice, it is well known that the signals of a 
chronic inflammation can result in the inappropriate recruitment of leukocytes and cause 
localized or disseminated tissue dysfunction and damage. The “leukocyte extravasation 
signaling” pathway seems, in fact, the most sustained both at 3 and 15 days. We show here that 
a considerable number of molecules involved in this pathway are altered, at least 3 days after the 
last LPS injection. Among these is the increased expression of the genes encoding for ICAM-1, 
selectin P ligand (Selpl), glycosylation dependent cell adhesion molecule 1 (Glycam1), mucosal 
vascular addressin cell adhesion molecule 1 (Madcam1), matrix metalloproteinase 23 (Mmp23). 
Other molecules such as chemokines are essential for the trafficking of inflammatory cells from 
the blood into tissues. Chemokine ligand 7 (Ccl7) and chemokine (C-C motif) ligand 13 (Ccl13) 
are up-regulated both at 3 and 15 days. Other relevant gene found up-regulated and that is 
involved in the migration of immune cells is interleukine-16 (IL-16). Of notice, we did not find IL-
16 influenced by acute inflammation. IL-16 is a pleiotropic cytokine that is a natural ligand of 
CD4 (Berman et al., 1985; Cruikshank and Center, 1982) and has been identified at sites of 
allergic inflammation in both the murine and the human airway epithelium (Laberge et al., 2000; 
De Bie et al., 2002). It is known as a chemoattractant for CD4+ T cells, monocytes, eosinophils 
and dendritic cells, with preferential chemoattractant activity for the Th1 subset of CD4+ T cells 
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(Kaser et al., 1999; Lynch et al., 2003; McFadden et al., 2007). Despite the increase in 
molecules that participate in leukocyte recruitment, no changes were observed in the expression 
levels of genes that encode tight junction proteins. Therefore, and contrary to what we previously 
observed in the acute response, the CP seems to more easily assure the integrity of the barrier in 
response to a sustained inflammatory stimulus. 
The CP response seems to share some mechanisms previously described at the BBB, which 
include the activation of adhesion and chemoattraction signals in endothelial cells in CNS 
diseases such as MS (Bullard et al., 2007; Engelhardt and Ransohoff, 2005). Therefore, both the 
blood-CSF barrier and the BBB seem equipped to convey signals to the brain parenchyma in 
response to both acute and chronic inflammation. 
When compared to the data obtained after a single bolus injection of LPS, the present data allow 
us to address the phenomenon of endotoxin tolerance described for bacterial LPS. It seems that 
the fold change is considerably smaller for genes whose expression is found altered both in 
response to acute and chronic LPS administration. While this could be related with the tolerance 
to LPS, future experiments should further investigate this possibility by analyzing the gene 
expression profile soon (e.g. 3h) after the last LPS injection. 
Despite the apparent tolerance to LPS, the expression of some CP genes seems solely altered after 
the chronic stimulation. Among these are genes encoding proteins of the S100 family. The S100 
family of calcium-binding proteins comprises a new group of pro-inflammatory molecules that have 
been discussed in the context of MS (Giovannoni, 2006) and in AD (Geroldi et al., 2006). Here we 
show increased levels of S100a8 and S100a9. It would next be interesting to investigate precisely 
the cell types expressing these proteins within the CP, and whether its levels are altered in the CSF 
of patients with MS and AD. Another molecule exclusively expressed during the chronic treatment is 
the macrophage scavenger receptor 2 (Msr2). Scavenger receptors (SRs), initially described as 
high-affinity receptors on macrophages for acetylated low-density lipoproteins, comprise several 
receptor classes (Husemann et al., 2002; Murphy et al., 2005) and are expressed in various cell 
types. SRs have a role in the binding and internalization of many unrelated ligands, such as fibrillar 
β-amyloid, lipids, glycated collagen and apoptotic cells, and, therefore, are important for tissue 
homeostasis. The up-regulated expression of this gene in the CP could indicate the possible 
protective role of the CP in the progression of diseases such as AD. As referred to above, clearance 
of amyloid β peptide out of the brain is reported to occur through the megalin and low-density 
lipoprotein receptor-related protein receptors that are SR (Zlokovic, 2004). 
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In summary, we describe here that the CP displays a sustained response to a continuous 
inflammatory stimulus induced in the periphery. The altered gene expression profile includes the 
up-regulation of genes encoding for both neuroprotective and deleterious molecules. Therefore, 
future studies should further investigate the final balance of the CP response in the context of 
diseases of the CNS. 
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General discussion 
The work developed during this thesis shows that the CP mounts a complex response to an 
inflammatory peripheral stimulus. The response of these cells alters the composition of the CSF 
and, consequently, might influence several regions of the brain parenchyma. Moreover, the 
pattern of genes up- and/or down-regulated in response to a single stimulus (acute inflammation) 
or repeated stimuli (sustained inflammation) differs greatly. The potential consequences of these 
differences will be discussed below. 
 
Most studies addressing the interactions between the periphery and the CNS focus on the BBB 
(Banks and Kastin, 1991; Banks, 2005; Engelhardt and Ransohoff, 2005; Engelhardt, 2006). 
The BCSFB represents also an important route between the periphery and the CNS, but has 
been poorly investigated. The CP is ideally located to respond to peripheral stimulus since it is 
well vascularised by fenestrated capillaries and because it produces most of the CSF. An altered 
profile of proteins secreted into the CSF may affect CNS function in health and in disease, and 
the composition of the CSF has been found altered in several neurological and psychiatric 
diseases. Of relevance, many of such disorders, including AD and MS are known to have as 
underlying inflammatory component. Thus, a more specific study on the profile of CP secreted 
proteins during inflammation may provide key information on physiological and pathological 
conditions. 
Several studies have previously identified CP receptors and immune modulators whose 
expression is found altered upon various systemic or intra cerebral inflammatory stimuli (Xia et 
al., 2006; Thibeault et al., 2001; Nadeau and Rivest, 1999; Brochu et al., 1999; Tonelli et al., 
2003; Wolburg et al., 1999; Engelhardt et al., 2001; Lopez et al., 1999; Carrithers et al., 2000). 
Most of these studies did not address specifically the CP, but rather several regions of the CNS 
focusing the attention on particular proteins. 
In the present study we considered the CP as a whole as an attempt to identify the molecular 
pathways involved in the response to inflammation and the impact on the CSF composition. 
The main achievements of the work developed in this thesis are that:  
1. The CP mounts an acute response to a single peripheral inflammation stimulus. This 
response induces alteration in the expression profile of a set of genes, occurs rapidly (can be 
detected as soon as 1h after LPS injection) and is transient (the profile of gene expression is 
almost back to normal 72h after the stimulus); 
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2. The CP response differs greatly if the stimulus is administered repeatedly. 
3. The CP seems to participate in modulating iron availability for the brain in conditions of 
inflammation.  
 
The overall choroid plexus response to peripheral lipopolysaccharide administration 
We first studied how the expression of major CP proteins responds to LPS. We chose to analyse 
the expression of TTR and TF because they are two liver negative acute-phase proteins (Ceciliani 
et al., 2002). In addition we decided to study lipocalin-type prostaglandin D2 synthase (L-PTGDS) 
because it is the second major protein synthesised by the CP and is responsible for the 
production of the major prostanoid of the CNS. We showed that the expression of L-PTGDS is 
increased upon LPS administration. Because prostaglandin D2 (PGD2) like other prostagladins 
has been implicated as a mediator for both pro- and anti-inflammatory actions it is difficult to 
conclude about the beneficial/detrimental effects of this increase (Harris et al., 2002; Urade and 
Hayaishi, 2000). Recently it has been suggested that endogenous PGD2 might display anti-
inflammatory properties, given its readily conversion to bioactive cyclopentenone-type 
prostaglandins of the J2-series such as 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) (Mouihate 
et al., 2004; Straus and Glass, 2001). It has been shown that 15d-PGJ2 regulates important 
biological responses, including protection against oxidative stress (Oh et al., 2008; Napimoga et 
al., 2008). However, in specific circumstances, 15d-PGJ2 also has pro-inflammatory properties 
(Harris et al., 2002); so the final relevance of its increased levels remains to be clarified. Because 
within the brain L-PTGDS is also synthesized by oligodendrocytes it will next be interesting to 
investigate whether the LPS stimulus also induces L-PTGDS expression in other brain regions. 
This might be particularly relevant in light of the recent description of L-PTGDS immunoreactivity 
in AD and in MS patients (Kagitani-Shimono et al., 2006; Kanekiyo et al., 2007). Additional 
studies on this subject should be performed in animal models of both diseases. 
 
These initial observations prompted us to investigate the overall response of the CP to LPS. 
Microarray analysis of the kinetic response to a single LPS injection revels that several major 
biological pathways are quickly and transiently altered. These pathways include a decrease in the 
expression of genes encoding tight junction proteins, which might compromise the CP barrier 
function; and the up-regulation of genes encoding proteins that promote cell migration, which 
may facilitate leukocyte entry into the brain. 
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Of interest the CP response includes the up-regulation of genes encoding pro- and anti-
inflammatory molecules. The levels of several of those were also increased in the CSF. Weather 
the final balance is protective or deleterious for the brain, specifically to neurons and glial cells, 
requires further investigation. Future studies should address the precise fate of these proteins 
secreted into the CSF in response to inflammation; both through the intrathecal administration of 
radiolabeled proteins and through studies on their effects on neuronal and glial cultures in vitro.  
In response to LPS, the levels of several cytokines increases in the bloodstream. Therefore, the 
CP response certainly reflects the influence not only of LPS but also of cytokines such as IL-1β, 
and/or IL-6, for which the receptors have been described in the basolateral membrane of the CP 
epithelial cells. In accordance, the expression of several genes belonging to intracellular pathways 
that respond to these molecules, and their downstream target genes were found altered in 
response to the LPS injection. Among theses genes are the JAK-STAT, MAPK, Nf-Kβ and IRFs 
signalling transduction pathways. 
Among the genes mostly altered in the acute-phase response is that encoding for LCN2. LCN2 
binds to bacterial siderophores, iron-chelators produced by bacteria as an attempt to acquire iron 
from the host. Since iron is requested for bacterial survival and replication, the host mounts an 
innate response in which several iron-binding proteins participate. The expression of LCN2 had 
been previously shown to be up-regulated in neutrophils, macrophages, adipocytes and in the 
liver, in response to peripheral infection and inflammation (Zhang et al., 2008; Borregaard and 
Cowland, 2006; Borregaard et al., 2007; Sunil et al., 2007). Of notice, LCN2-null mice exhibit 
increased susceptibility to infection by bacteria that depend on entherocalin-like siderophore-
dependent iron uptake (Berger et al., 2006; Flo et al., 2004). However, none of the studies done 
previously addressed the role of LCN2 in the brain. The fact that we now observed a strong LCN2 
expression in the CP, which results in increased CSF LCN2 levels, suggests that the CP 
participates in the innate response to infection. Whether the lower susceptibility of the brain to 
various agents depends on LCN2 is an interesting question to investigate. Future studies should 
address, in vivo, how LCN2 protects the brain from infection by bacteria. In addition, it will also 
be useful to investigate whether the ability of bacteria to access and colonize the brain depend on 
the amount of LCN2 produced by the host. Meningitis are among the most serious and deadly 
infections. Major bacterial meningitis pathogens are Neisseria meningitidis, Haemophilus 
influenzae and Streptococcus pneumoniae. As neither S. pneumoniae nor H. influenzae are 
known to produce or utilize siderophores, they may have developed siderophore-independent 
 122
mechanisms to acquire iron. The specific expression of iron-related genes in the CP (please see 
below) is now warranted both for bacteria that normally colonize or are prevented from colonizing 
the brain. It will also be interesting to study how administration of LCN2 interferes with the 
course of infection by Mycobacterium tuberculosis, a microorganism also known to be able to 
cause meningitis and that produces siderophores (Miethke and Marahiel, 2007). It should lastely 
be mentioned that while no mammalian siderophores have ever been identified, other functions 
have been suggested for LCN2 in iron homeostasis, particularly in iron delivery to cells. Whether 
this may be relevant during development, before the onset of TF expression, or in specific 
conditions such as inflammation is certainly worth exploiting further. This may be particularly 
relevant since up-regulated LCN2 expression remains when LPS is administered repeatedly. 
These observations prompted us to characterize, in the CP, other molecules involved in iron 
homeostasis.  
 
Iron metabolism in the brain after peripheral inflammation 
In the context of response to inflammation, iron metabolism seems an interesting issue. Iron is 
essential for the basic cellular functions but it can also have deleterious effects essentially 
because its accumulation can contribute to production of damaging reactive oxygen species 
(ROS) (Brewer, 2007). ROS formation leads to oxidative stress when there is an imbalance in the 
redox status of a cell. This is described to occur in various neurodegenerative and 
neuroinflammatory disorders such as AD and PD (Zecca et al., 2004; Qian and Wang, 1998). 
Furthermore, there is evidence suggesting that iron deficiencies, during pregnancy or early during 
postnatal development, can cause mental disorders and severe motor impairments (Lozoff et al., 
1991). Therefore, by modulating iron availability for the brain, specifically in the CSF, the CP may 
have a relevant function in response to a potential brain infection but also in neurodegeneration 
of the CNS. 
Understanding the timing of iron mismanagement in relation to various pathological conditions 
may provide information on pathogenesis and on susceptibility to conditions such as infection by 
pathogens. This may be particularly relevant if these changes are a consequence of breakdown 
of the BBB and BCSFB that allows more iron to access the brain. 
Surprisingly our observations suggest that the CP rapidly responds in order to prevent iron release 
into the CSF upon a peripheral inflammatory stimulus. This response includes not only the 
expression of hepcidin, a key modulator of iron homeostasis, but also ceruloplasmin and transferrin 
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receptor type 2 (TFR2). Preliminary data suggest that the molecular pathway triggering hepcidin 
expression in vivo may be mediated by the TFR2 since IL-6 fails, in vitro, to stimulate its expression. 
These observations encourage us to propose additional studies on iron metabolism, both in chronic 
inflammation but also in models of neurodegenerative disease such as MS and AD. 
 
New insights from the sustained inflammation 
It is known that in response to a peripheral inflammation or infection, innate immune cells 
produce pro-inflammatory cytokines that act on the brain to cause sickness behaviour (Konsman 
et al., 2002). When activation of the peripheral immune system continues, such as during 
systemic infections, cancer or autoimmune diseases, the resulting immune signalling to the brain 
can lead to an exacerbation of sickness and the development of symptoms of various CNS 
disease including depression (Dantzer et al., 2008) and exacerbation of motor neuron disease 
(Nguyen et al., 2004). In addition, several evidences suggest that a chronic inflammatory 
component is implicated in the appearance and in the progression of neurodegenerative diseases 
such as MS and AD. Here we used a model of multiple injections of LPS, every two weeks, for 
three months, as an attempt to mimic a sustained inflammatory response. We chose to sacrifice 
the animals at two time points: 72h after the last LPS injection, in order to distinguish between 
the genes whose expression corresponded to the acute effect of the last LPS injection (studied 
72h after a single injection of LPS in the acute response) from those that represent a sustained 
response; and 15 days after the last LPS treatment, to address the genes whose expression 
remains continuously altered. When we compared with the acute-response the expression of 
much less genes was found altered, and the fold changes observed were also smaller. However, 
since the altered expression of some genes seems to be sustained, the effect in the overall 
expression, and the impact on the CSF composition, may be equally relevant. Among the 
pathways mostly up-regulated is that of adhesion molecules that might promote migration of 
immune cells into the brain. This observation reinforces the idea of the CP as a possible place of 
entry of the immune cells, in addition to the better studied BBB route. This may be particularly 
relevant for diseases such as MS. In fact, the pathogenesis of MS is also characterized by a 
massive entry of inflammatory auto-reactive T cells in the parenchyma of the CNS in which the 
CP has been proposed to participate (Strazielle and Ghersi-Egea, 2000; Brown and Sawchenko, 
2007). Of notice the demyelination plaques in MS are frequently located in the periventricular 
area, wich is easily influenced by molecules and cells reaching the CSF through the CP. In this 
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work we show that in response to sustained inflammation the CP synthesizes molecules 
(chemokines and adhesion molecules) that are strong candidates to promote leukocytes 
adhesion and extravasations from the periphery into the brain. Ongoing studies are addressing 
whether the CP expression profile in MS shares similarities with that observed during response to 
peripheral inflammation. Preliminary results have shown LCN2 among the highly expressed 
proteins, further suggesting that LCN2 may have another function in addition to the known ability 
to bind bacteria siderophores. 
 
The relevance of the CP response to sustained inflammation is not limited to the fact of being a 
place of immune cells entry but also as a site for microorganism invasion into the brain. Some 
pathogen-induced inflammation occurs within the CP given the tropism to epithelial cells that 
bacteria, parasites and viruses such as Neisseria meningitidis, Trypanosoma brucei, Sendai 
virus, mumps virus and perhaps even HIV-1 and human T cell leukemia virus-1 (HTLV-1) present. 
In fact, they have been shown to accumulate preferentially into the CP (Petito and Adkins, 2005). 
The data we present here highlight certain antimicrobial proteins such as lysozyme and LCN2 
that may be important to fight brain infection. Whether these, or others, may become interesting 
targets for novel therapeutic approaches should certainly be further investigated.  
 
Choroid plexus as a component of the neuroimmune system - possible contribution 
of stromal cells 
It will be next important to discuss the involvement of other cell types present in the CP stroma, 
namely those of the lymphoid lineage, in the overall CP response to inflammatory stimuli. The CP 
should be viewed, in our perspective, as a small and complex organ. For that contributes the fact 
that the CP is formed by cuboidal epithelial cells resting upon a basal lamina and central core of 
connective and highly vascularised tissue. Globular macrophages, dendritic cells (Ling et al., 
1998; McMenamin et al., 2003; Hanly and Petito, 1998), and fibroblasts are found throughout 
the stroma; while epiplexus cells are located on the apical surface of the epithelial cells (Emerich 
et al., 2005; Ling et al., 1998). Therefore, when CP is removed from the brain ventricles, it 
certainly counts with the contribution of proteins expressed by all the different cell types. This 
may be particularly relevant in situations of infection or inflammation because of the immune 
cells that are travelling in the bloodstream in such conditions. It is therefore necessary to 
discriminate, by immunohistochemistry, in situ hybridization or laser microdissection of particular 
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cells types and/or by using in vitro models of CP epithelial cells, in which cell types, each 
individual proteins is expressed. As shown in chapter 3 for LCN2, this protein is expressed both 
by the CP epithelial cells and also by endothelial cells of the blood vessels. Other acute-phase 
proteins, known to be produced in response to inflammation by neutrophils and macrophages, 
may also contribute to the overall CP expression profile shown here. Another aspect that we 
should always consider is that when LPS is injected in the periphery, it also elicits a peripheral 
immune response. This results in the expression of several immune mediators by several blood 
circulating cells, and by those present in the CP stroma. These molecules reach and activate 
receptors in the basal membrane of the CP epithelial cells. Therefore, and as mentioned before, 
all these other cell types ultimately contribute to the overall CP response to inflammation.  
The question on how the CP responds to inflammation induced within the brain has not been 
addressed in the present study, but it is certainly of relevance, keeping in mind that some 
inflammatory response may be elicited within the brain by, for instances, neuronal degeneration. 
This may as well be relevant in the neurodegenerative disorders mentioned before. Of notice, the 
CP has been proposed as a site of exit of proteins such as the AD amyloid β peptide (Carro et al., 
2005; Zlokovic et al., 1996). This is proposed to occur through receptors (e.g. megalin) present 
in the CP apical membrane, and mediated by proteins the CP secretes into the CSF (e.g. TTR, 
cystatin C, apolipoprotein J). Future studies should, therefore, not only study the CP expression 
profile in diseases such as AD, but also the overall CP response to inflammatory stimulus elicited 
both in the circumventricular space and within the brain parenchyma. In such an approach, it will 
also be interesting to evaluate the epithelial interaction with dendritic cells in regulating antigen 
sensitization to the periphery. It has been shown in the intestine and in the airways epithelia that 
intraepithelial dendritic cells extend processes into the intestinal or airway lumen, respectively, to 
collect antigenic material from the mucosa surface (Schleimer et al., 2007; Shaykhiev and Bals, 
2007, Kato and Schleimer, 2007). Whether such interaction also occurs between the dendritic 
cells within the CP epithelium and the ventricular space of the brain can eventually be visualized 
by electronic microscopy. 
 
In summary, the work presented in this thesis highlights the CP as a relevant mediator in the 
interaction between the immune system and the CNS, raising numerous exciting questions for 
studies to be launched in the near future.  
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